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STAT3 Contributes to Resistance Towards BCR-ABL Inhibitors in a Bone
Marrow Microenvironment Model of Drug Resistance
Nadine N. Bewry

ABSTRACT

Imatinib mesylate (imatinib) represents a potent molecularly targeted
therapy against the oncogenic tyrosine kinase, BCR-ABL. Although imatinib has
shown considerable efficacy against chronic myeloid leukemia (CML), displaying
high rates of complete hematological and complete cytogenetic responses,
treatment with imatinib is not curative and overtime advanced-stage CML
patients often become refractory to further treatment. Acquired resistance to
imatinib has been associated with mutations within the kinase domain of BCRABL, BCR-ABL gene amplification, leukemic stem cell quiescence as well as
over-expression of the multidrug resistance (MDR1) gene. However, in vitro
resistance models often fail to consider the role of the tumor microenvironment in
the emergence of the imatinib-resistant phenotype. The bone marrow is the
predominant microenvironment of CML and is a rich source of both soluble
factors and extracellular matrixes, which may influence drug response. To
address the influence of the bone marrow microenvironment on imatinib
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sensitivity, we utilized an in vitro co-culture bone marrow stroma model. Using a
transwell system, we demonstrated that soluble factors secreted by the human
bone marrow stroma cell line, HS-5, were sufficient to cause resistance to
apoptosis induced by imatinib in CML cell lines. We subsequently determined
that culturing CML cells in HS-5-derived conditioned media (CM) inhibits
apoptosis induced by imatinib and other second generation BCR-ABL inhibitors.
These data suggest that more potent BCR-ABL inhibitors will not overcome
resistance associated with the bone marrow microenvironment. Additionally, we
determined that CM increases the clonogenic survival of CML cells following
treatment with imatinib. HS-5 cells are reported to express several cytokines and
growth factors known to activate signal transducer and activator of transcription 3
(STAT3). Given its crucial role in the survival of hematopoietic cells, we asked
whether, 1) CM derived from HS-5 cells can activate STAT3 in CML cells and 2)
does activation of STAT3 confer resistance to BCR-ABL inhibitors. We
demonstrated that exposure of the CML cell lines, K562 and KU812, to CM
caused an increase in phospho-Tyr STAT3, while no increases in phospho-Tyr
STAT5 were noted. Moreover, resistance was associated with increased levels of
the STAT3 target genes, Bcl-xl, Mcl-1 and survivin. Furthermore, reducing
STAT3 levels with siRNA sensitized K562 cells cultured in CM to imatinibinduced cell death (p<0.05, Student’s t-test). Importantly, STAT3 dependency
was specific for cells grown in CM, as reducing STAT3 levels in regular growth
conditions had no effect on imatinib sensitivity. Together, these data support a

xiv

novel mechanism of BCR-ABL-independent imatinib resistance and provide
preclinical rationale for using STAT3 inhibitors to increase the efficacy of imatinib
within the context of the bone marrow microenvironment.

xv

CHAPTER I
INTRODUCTION

Hematopoiesis
Although an estimated 1 x 1010 red blood cells and 1 x 109 white blood
cells are produced per hour, mature blood cells have a limited lifespan of only a
few hours to a few days and, therefore, require continuous production.
Hematopoiesis is the highly regulated process of blood cell production from
hematopoietic stem cells (HSCs) within the bone marrow (Figure 1). This
process, which continues throughout adulthood, first begins in the embryonic yolk
sack during the first weeks of embryonic development, proceeds in the liver and
then the spleen. In adults, the bone marrow becomes the major site of
hematopoiesis and ceases in the liver and spleen. The primary locations of HSC
production are femurs, hip, ribs, sternum, as well as other bones.
HSCs are small, non-adherent, rounded cells that possess a rounded
nucleus and can be identified by their low cytoplasm-to-nucleus ratio.
Characterized by their multipotency and high replicative and differentiation
capacity, HSCs are capable of giving rise to all types of blood cells, which are
divided into three distinct lineages: lymphoid, myeloid and erythroid. The
lymphoid lineage of HSCs is composed predominantly of T-cells and B-cells, a
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category of leukocytes or white blood cells (WBCs) called lymphocytes. Although
they are the smallest WBCs, they are the cornerstones of the immune system,
playing vital roles in the cell-mediated and humoral components of adaptive
immunity, respectively. This lineage also consists of natural-killer (NK) cells,
which plays a central role in defending the body from both tumors and virally
infected cells. The myeloid lineage produces another category of leukocytes that
include granulocytes, megakaryocytes and macrophages. Granulocytes, also
known as polymorphonuclear leukocytes (PMN or PML) because of the varying
shapes of the nucleus, consist of: 1) basophils, the least common of the
granulocytes that play a role in regulating the immune inflammatory response to
allergens and drugs; 2) eosinophils, which also respond to allergens and are
involved in defending against infection and parasites; and 3) neutrophils, the
most abundant WBCs in the body that contain granules of bacteria-killing
enzymes in their cytoplasm and function as phagocytes, responding primarily to
acute inflammation due to bacterial infection or fungi. Megakaryocytes produce
blood platelets, which are small cells necessary for normal blood clotting.
Macrophages are phagocytes involved in both innate and adaptive immunity. The
third lineage of HSCs, the erythroid lineage, gives rise to oxygen-carrying red
blood cells (RBC), which make up 45% of blood volume.

2

Figure 1. The Process of Hematopoiesis. All of the cellular components of the
blood are derived from hematopoietic stem cells. Blood cells are divided into
three lineages: lymphoid, myeloid and erythroid.
Types of Leukemia
Hematopoiesis is highly regulated by a balance of growth and death
signals that determine the fate of each cell in the hematopoietic system.
Consequently, mutations of stem cells can disrupt the hematopoietic system to
confer a growth advantage. This deregulated hematopoiesis creates an
imbalance between cell production, destruction and differentiation and can lead
to a number of hematologic diseases. Leukemia, the abnormal proliferation of
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blood cells in the bone marrow, results in deregulated blood cell production and
cell differentiation.
Leukemia is classified as acute or chronic based on pathological and
clinical characteristics, such as the speed with which the disease progresses and
the phenotype of the affected cells. While acute leukemia is distinguished by the
rapid increase of WBCs, an increase in mature, yet abnormal blood cells typifies
chronic leukemia. Leukemia can be further sub-divided as lymphoid or myeloid
based on the lineage of the blood cells that are affected (Table 1).

Normal vs. Leukemic Hematopoietic Stem Cells
Normal HSCs are a rare, quiescent homogeneous cell population whose
production is very tightly regulated. Additional characteristics of stem cells
include their multipotent differentiation capacity and their ability to self-renew [1].
4

Based on the latter characteristic, HSCs can be subdivided by their stem cell
hierarchy, or the degree to which they are able to self-renew, as short- or longterm repopulating cells [2].
Despite major advances in our understanding of stem cells, little is known
about their role of stem cells in human malignancies. There is a growing body of
evidence that lends support to the existence of cancer stem cells (CSCs), a
small, primitive subpopulation of cancer cells that escape normal control and are
capable of initiating, propagating and maintaining the cancer cell population [3].
Studies show that CSCs have been implicated in a number of human
malignancies, including breast and brain tumors [4, 5].
Among the CSC subpopulation, studies have identified and characterized
cancer-causing leukemic stem cells (LSCs). These cells share many of the
canonical properties of normal HSCs, such as multipotency, the ability to selfrenew, and extensive proliferative capacity [6, 7]. However, unlike normal HSCs,
these LSCs display a reduced or absent exogenous growth factor-dependence
[8]. Instead, these cancer-causing leukemic cells are capable of generating their
own growth signals, most notably via the autocrine production of cytokines such
as interleukein-3 (IL-3) and/or granulocyte colony-stimulating factor (GM-CSF)
[9].
Early studies using immunodeficient mice as xenotransplantation models
demonstrated the existence of leukemia-initiating stem cells in CML patients [1013]. Like normal stem cells, these cells lack lineage markers (Lin-) and are
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distinguished as follows: CD34+CD38- Thy-1+Lin- (Baum C, 1992), where CD34
is a single-pass transmembrane glycoprotein that functions as a cell-cell
adhesion factor and is expressed early in hematopoietic tissues [14]; CD38 is an
early cell surface marker for white blood cells [15] and CD90 or Thy-1 is the
thymocyte (T-cell precursor) marker [16]. Research done in these early CML
models confirmed that while chronic phase CD34+ CML patient cells contained
both normal and LSC fractions, patients in blast crisis phase CML have a greater
preponderance of LSCs [17]. CML LSCs are not composed of a functionally
homogeneous cell population as previously believed, but like normal HSCs, are
comprised of a heterogeneous pool of short-term and long-term repopulating
cells [18-20].
Addressing the failures of cell cycle-active chemotherapeutic agents to
eradicate CSCs in vivo and in vitro poses a challenge for CML patient care, as
primitive quiescent cells are resistant to imatinib. This resistant, quiescent LSC
phenotype coupled with an augmented stem cell population, an enhanced selfrenewal capacity and decreased growth-factor dependence/increased autocrine
secretion of growth factors may contribute to chemo-resistance in CML patients
and subsequent relapse.

6

CHAPTER II
CHRONIC MYELOID LEUKEMIA AND THE ‘PHILADELPHIA’ CHROMOSOME

Currently within the United States every 1 in 4 deaths is due to cancer
[21]. Among cancers, chronic myeloid leukemia (CML) is possibly the most wellstudied. CML is a myeloproliferative disorder that is characterized by the
neoplastic transformation and malignant expansion of pluripotent hematopoietic
stem cells (HSCs) within the bone marrow resulting in cancer of the white blood
cells. It accounts for 7% to 20% of all cases of leukemia, and according to the
America Cancer Society estimates, in 2008 there will be 4,830 newly diagnosed
cases of CML with 450 of those resulting in deaths. While it affects all age
groups, it is predominantly affects middle-aged to elderly individuals at a rate of
1-2 per 100,000. CML is the first disease to be linked to a clear, consistent
genetic abnormality, the Philadelphia (Ph’) chromosome, which was first
described in 1960 by Peter Nowell of the University of Pennsylvania and David
Hungerford of the Fox Chase Cancer Center, two scientists from Philadelphia,
Pennsylvania [22]. The team described a tiny acrocentric chromosome in cells
cultured from the blood of seven patients harboring the disease. This
chromosome later became the unique genetic signature and diagnostic clinical
marker of CML patients [23]
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The Ph’ chromosome is formed by the reciprocal translocation and fusion
between the long arms of chromosomes 9 and 22 [t(9,22)(q34;q11)] [24-26] (see
Figures 2A and B). Chromosome 9 encodes the proto-oncogene ABL, while
chromosome 22 encodes the breakpoint cluster region gene (bcr), a
serine/threonine kinase named after the site where it is located. This
translocation event results in the formation of the chimeric oncogene, BCR-ABL,
which gives rise to an aberrant and deregulated, constitutively active tyrosine
kinase capable of activating numerous downstream targets.

8

Figure 2: The Philadelphia (Ph’) chromosome. CML is the first disease to be
linked to a clear and consistent genetic abnormality, the Philadelphia
chromosome. (A) Human karyotype, with chromosomes 9 and 22 highlighted; (B)

9

Formation of the Philadelphia chromosome. The Philadelphia chromosome is
formed by the head-to-tail reciprocal translocation between the long arms of
chromosome 9, which contains the proto-oncogenic ABL non-receptor tyrosine
kinase, and chromosome 22, which contains the bcr serine/threonine kinase
[t(9:22)(q34:11)].
CML is divided into three phases based on clinical characteristics that
such as the amount of blast cells (immature, abnormal white blood cells) in the
blood and bone marrow and the severity of symptoms presented (see Table 2).
The initial chronic phase (CP), diagnosed in approximately 95% of patients, has
an average duration of 4 to 6 years and is often asymptomatic, or patients may
experience mild symptoms of fatigue, anemia, splenomelgaly, upper abdominal
pain or mass. Less common presentations may include fever, weight loss,
anorexia or gout. Chronic phase CML is characterized by an overproduction of
immature myeloid and mature granulocytes in the spleen, peripheral blood and
bone marrow; however, the cells retain the ability to differentiate and function
normally. The lack of therapeutic intervention and the presence of additional
genetic and/or epigenetic defects cause the disease to progress to an
accelerated phase (AP), characterized by the presence of 10–20% primitive blast
cells in the peripheral blood and bone marrow. When the disease advances to
the ‘blast-crisis’ phase it resembles acute leukemias and is characterized by the
presence of >20% undifferentiated blasts in the peripheral blood and bone
marrow. At this grave stage patients have a life expectancy of 3-6 months.
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While the cause of the initial translocation event which gives rise to CML
remains unclear, studies have shown that translocation can be induced by
ionizing radiation (IR) [27]. Additionally, the physical distance between the BCR
gene and the ABL gene in human hematopoietic progenitor cells is shorter than
might be expected by chance and could favor translocation between the two
genes [28, 29].
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The BCR-ABL Protein
BCR-ABL’s oncogenic capacity is mediated by its multiple modular
domains inherited from BCR and ABL that facilitate diverse protein-protein
interactions (some of BCR-ABL’s protein targets are described in Table 3).
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Structure of c-BCR Protein
The 160-kd (p160) breakpoint cluster region protein, BCR, is a large multidomain, ubiquitously expressed serine/threonine kinase comprised of 1,271
amino acids (Figure 3). At its NH2-terminus, BCR has a coiled-coil/oligomeric
domain which enables the protein to dimerize in vivo [30]. The serine/threonine
kinase domain defines the protein’s function by phosphorylating substrate on
either serine or threonine residues. Known substrates of BCR include Bap-1, a
member of the 14-3-3 family of proteins [30, 31] and BCR itself [32]. Within the
center of the protein is the Rho/guanine nucleotide exchange factor (Rho/GEF)
domain that is specific for the Rho-subfamily of small GTPases, RhoA and
CDC42. Both small GTPases regulate actin cytoskeleton rearrangement and
control cell functions such as cell migration, morphology and cell cycle
progression. The Rho/GEF domain also interacts with and activates transcription
factors such as NF-kB [33]. This domain is followed by the Pleckstrin homology
(PH)/Calcium-dependent lipid binding (CaLB) domain that binds phospholipids,
such as phosphotidylinositides (PI). This interaction plays an important role in
signal transduction by localizing the protein to cellular membranes and activating
second messenger. The carboxyl-terminus of the protein contains a Rac-GTPase
activating protein (Rac-GAP) domain [34], a small GTPase belonging to the Ras
super-family that plays a role in regulating actin polymerization. Additionally,
BCR’s tyrosine 177 (Y177) residue is an autophosphorylation site that is
essential for binding to the adaptor molecule, GRB-2, and activating the mitogen
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activated protein kinase (MAPK) signal transduction pathway. BCR-ABL
autophosphorylation also occurs on Y283, Y328 and Y360 [35-37].

Figure 3: Structural Domains of The c-BCR Protein. There are several
functional domains found within BCR: At its N-terminus lies an oligomerization
domain; this is followed by a serine/threonine kinase domain; a Rho/Guanine
nucleotide exchange factor (Rho/GEF) domain; a Pleckstrin homology (PH)
domain and a Rac-GTPase activating protein (Rac-GAP) domain. Key residues
include Y177 which enables mitogenic activation of the MAPK pathway via
binding of the adaptor molecule GRB-2.
Structure of c-ABL Protein
The c-ABL gene was initially identified as the human homologue of the
Abelson murine leukemia virus (A-MuLV), which is the acute transforming
retrovirus encoding the v-ABL oncogene [38]. It is located on chromosome 9q34,
spans 230 kilobases (kb) and possesses 11 exons that encodes a 145 kilodalton
(kD) (1,097 amino acids) non-receptor tyrosine kinase. In addition to c-ABL, the
ABL family of non-receptor tyrosine kinases is also comprised of ARG (ABLrelated gene, designated ABL2).
Like BCR, ABL is expressed ubiquitously within the cell, but predominates
within the nucleus and cytoplasm. Its diverse localization within the cell reflects
its diverse functions, which are mediated by its protein-protein interactions.
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These interactions facilitates ABL’s involvement in numerous cellular processes,
including cellular response to DNA damage and genotoxic stress [32, 39-41], cell
cycle regulation [28, 42] and rearrangement and cell migration [43]. There are
two isoforms, designated 1b and 1a, which are generated by alternative splicing
of the first exon (Figure 4) and are driven by their own promoters. Differing only
in their NH2-terminus sequences, the 1b isoform encodes a 6.5 kb mRNA, while
the 1a isoform encodes a slightly shorter 5 kb transcript that is 19 amino acids
shorter than 1b.
Within the amino-terminus of the 1b isoform lies a myristoylation site
which enables plasma membrane- attachment. This site is missing in the 1a
isoform. Further within the NH2-terminus are three SRC-homology domains,
SH1-SH3. The SH1 tyrosine kinase domain defines protein’s function. It contains
two key residues: Y412, the site of phosphorylation in transformed cells, and
Y393, the major site of autophosphorylation within the proto-oncogene’s kinase
domain. Both the SH2 and SH3 domains are involved in mediating proteinprotein interactions: the SH2 domain binds to the phosphotyrosine regions of
target proteins, while the SH3 domain recognizes proline residues. Within the
center of the protein is a proline-rich region (P) which, conversely, binds the SH3
domains of other protein substrates [44]. Towards the carboxyl-terminus there
are three (NLS) [42, 45], a DNA binding domain (DNA BD) [45], a nuclear
exporting signal (NES), and an actin-binding domain which mediates binding to
globular/ monomeric (G) and filamentous (F) actin.
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Figure 4: Structural Domains of The c-ABL Protein. There are several
functional domains found within ABL: a myristoylation site; SRC-homology (SH)
domains SH1-3; four proline-rich regions (P); three nuclear localization signal
(NLS) regions; a DNA binding domain (DNA BD; an actin binding domain and a
nuclear export signal (NES).
One BCR-ABL Oncogene, 3 BCR-ABL Proteins Isoforms
Breakpoints within the BCR gene results in primary fusion BCR-ABL
transcripts with the same portion of ABL sequence in the carboxyl-terminus, but
include different amounts of bcr sequence at the NH2-terminus (see Figure 5A).
Unlike ABL, which has only one breakpoint within a region greater than 300 kb at
its 5’ end, BCR’s breakpoints are localized within three ‘breakpoint cluster
regions’ (bcr) resulting in three BCR-ABL fusion proteins varying in size from 190
to 230 kD (Figure 5B). Each isoform is associated with a different type of
leukemia.
In 95% of CML patients and 1% Ph-positive acute lymphoblastic leukemia
(ALL) patients, the breakpoint occurs within the major breakpoint cluster region of
BCR (M-bcr), a 5.8 kb area stretching across exons b12-b16. These patients
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possess the p210 BCR-ABL isoform, which is formed when either exon b12 or
b13 of BCR fuses with exon a2 of ABL.
Most ALL patients possess the breakpoint within the minor bcr region (mbcr), which spans a 54.5 kb area between exons b1 and b2. The resulting p190
BCR-ABL fusion protein is characteristic of ALL.
The p230 BCR-ABL isoform is seen in patients with chronic neutrophilic
leukemia (CNL), a rare disease in which too many stem cells develop into
neutrophils. CNL may stay the same or progress quickly into acute leukemia. The
recently characterized mu-bcr (µ-bcr), is associated with this form of leukemia
and is located downstream of exon b19.
The research presented here is focused on the role of p210 BCR-ABL in
CML pathogenesis.
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Figure 5: 1 BCR-ABL Oncogene, 3 BCR-ABL Proteins Isoforms. Fusion
transcripts contain the same portion of the ABL within the carboxyl-terminus but
different amounts of BCR sequence at the amino-terminus depending on where
the breakpoints occur within BCR. (A), Breakpoint locations within the ABL and
BCR genes. 3 breakpoint cluster regions (bcr) are found within the BCR gene:
the major bcr (M-bcr), the minor bcr (m-bcr), and the mu bcr (µ-bcr). Breakpoints
within each of these regions give rise to a different form of leukemia. ABL has a
>300 kb breakpoint region between exons a1 and a2. (B), Structure of the
chimeric BCR-ABL transcripts. The p190 BCR-ABL isoform is found in Phpositive ALL, the p210 isoform is found in CML, and the p230 isoform is found in
CNL (Clinical Cancer Research Vol. 8, 2177-2187, July 2002).
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CHAPTER III
BCR-ABL PATHOGENESIS

The Role of Modular Domains
Features of key domains and motifs contribute to p210 BCR-ABLmediated malignant transformation in CML patients (Figure 6A). The
oligomerization domain of BCR performs several crucial roles: 1) it enables the
chimeric BCR-ABL proteins to form dimers (or tetramers) and to transautophosphorylate, which abrogates the need for regulatory external kinases
(see Figure 6B); 2) it is an essential activator of ABL kinase activity [30]; and, 3) it
promotes the association of BCR–ABL with F-actin which facilitates cytoskeletal
rearrangement, cell spreading and cell migration [43]. The GRB-2 binding site at
tyrosine 177 activates both the MAPK survival pathway [46, 47], and the
phosphatidylinositol 3-kinase (PI3K) anti-apoptotic pathway [47].
Purified ABL is kinase-active, therefore regulatory cis- and trans-acting
elements are believed to be involved in its constitutive inhibition. Intermolecular
interactions within the first three tandem domains of ABL facilitate their assembly
into an auto-inhibitory structure that negatively regulates the protein. The SH3
domain interacts with Pro1124 within the SH2-linker region and results in a
‘clamp’ structure that confines the kinase in an inactive confirmation [44, 48].
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Furthermore, the myristoylation site binds to the tyrosine-kinase domain of ABL,
operating as a ‘latch’ that reinforces the SH3–SH2 ‘clamp’ [48, 49]. Studies show
that the SH3 domain is intrinsically capable of suppressing the transforming
ability of ABL and its deletion or mutation fully activates the kinase [39].
Additionally, a number of proteins also bind to the SH3 domain of ABL and serve
as negative regulators of the proto-oncoprotein. ABL interactor proteins 1 and 2
(Abi-1 and Abi-2) bind to ABL’s SH3 domain and activate the inhibitory function
of this domain [50-52]. Additionally Pag/Msp23, another ABL SH3-binding
protein, dissociates from ABL under oxidative stress and facilitates its tyrosine
kinase activity [53].
Fusion of BCR with ABL breaks the intermolecular bonds within ABL’s SH
domains and disrupts its constitutively inhibited regulatory configuration.
Furthermore, activated ABL tyrosine kinase triggers the ubiquitin-proteasomemediated destruction of the Abi proteins that normally antagonize its oncogenic
potential [54].
Collectively, deregulation of BCR and ABL’s multiple domains is a major
contributing factor in CML pathogenesis.
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Figure 6: Structure of p210 BCR-ABL Protein. (A), BCR-derived sequences
and ABL-derived sequences. Fusion of BCR to ABL is central to the
pathogenesis of CML as it not only disrupts ABL’s regulatory configuration but
also disrupts BCR-ABL’s localization within the cell. (B), Location of transautophosphorylation sties within BCR-ABL. Proteins are able to dimerize via their
oligomerization domains and trans-self-phosphorylate on both Y177, a key
binding site for GRB-2, and Y1124 within the activation loop of ABL’s kinase
domain.
Activation of Multiple Signaling Pathways
BCR-ABL activates numerous pathways commonly used in hematopoietic
growth factor receptor signaling. These activated pathways contribute to CML
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pathogenesis by causing 1) constitutive mitogenic activation, inhibition of
apoptosis and decreased adhesion to bone marrow stroma extracellular matrices
(Figure 7).

Figure 7: Mechanisms of Malignant Cell Transformation by BCR-ABL. BCRABL-mediated malignant transformation in CML pathogenesis occurs via three
major mechanisms: constitutive mitogenic activation, inhibition of apoptosis and
decreased adhesion to bone marrow stroma extracellular matrices.
Constitutive Mitogenic Activation: The Ras/MEK Pathway
The Ras/extracellular-signal-regulated kinase (ERK) (Ras/ERK) transmits
extracellular signals into the nucleus and results in gene transcription [55-57].
The autophosphorylated Y177 residue within BCR-ABL’s first exon serves as a
docking site for growth factor-binding protein 2 (GRB-2)’s SH2 domain and

22

facilitates signal transduction (Figure 8). GRB-2 forms a complex with the
guanine nucleotide exchange factor, son of sevenless (SOS) protein, which
stabilizes RAS in its active GTP-bound conformation and induces its activation.
RAS activation can also be mediated by three other adaptor molecules and BCRABL substrates, SH2-containing protein (Shc), Crk-like protein (Crkl) and
phospho-protein p62DOK [58-60].
RAS activation initiates a cascade of signaling events involved in CML
pathogenesis. Activated Raf-1 (MAP KKK) phosphorylates MEK1/2 (MAP KK) on
both serine and threonine residues; MEK1/2 then phosphorylates and activates
the extracellular-signal regulated kinases, ERK1/2 (MAPK), which results in the
phosphorylation and activation of the transcription factor Elk1. Upon activation,
Elk-1 translocates to the nucleus and binds the serum response factor (SRF)
transcription factor. This ternary complex then binds the serum response element
(SRE) of the immediate early genes and proto-oncogenes, c-Fos and c-Jun, to
direct their transcriptional activation and regulation.
Together, c-Fos and c-Jun DNA-binding proteins heterodimerize to form
the AP-1 transcription factor which upregulates the transcription of genes
involved in cell proliferation, cell differentiation and mediating growth-factor
independence. These genes include the G1-cyclin dependent kinases (CDKs)
[61]; CDK regulator, cyclin D1 [62]; c-Jun [63]; the anti-apoptotic protein Bcl-xL
[64]; granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic
cytokine [65]; the second messenger, cyclic adenosine monophosphate (cAMP)
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[66]; and cAMP response element binding protein (CREB) [67]. The upregulation
of these genes is characteristic of CML pathogenesis.

Figure 8: BCR-ABL Activates the Ras/MEK Mitogenic Signal Transduction
Pathway. Autophosphorylation of BCR-ABL on Y177 results in its interaction with
the adaptor molecule, GRB-2. GRB-2 interacts with the guanine nucleotideexchange factor, SOS, which in turn mediates RAS activation. The adaptor
molecules Shc and Crkl can also mediate RAS activation. RAS is coupled to the
mitogen activated protein kinase (MAPK) pathway by the serine/threonine
kinase, Raf. Raf in turn phosphorylates mitogen activated and extracellular-signal
regulated kinase kinases 1 and 2 (MEK1/2). This lead to a phosphorylation and
activation of and extracellular-signal regulated kinase kinases 1 and 2 (Erk1/2)
and the subsequent activation of the transcription factor Elk.
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Inhibition of Apoptosis
The PI3/AKT Pathway
The lipid kinase phosphoinositide 3-kinase (PI3K) represents a family of
cytosolic, intracellular signaling proteins whose deregulation is associated with
malignant cell transformation [68]. Class I PI3Ks, which are commonly activated
in CML, are heterodimeric molecules that are composed of a regulatory and a
catalytic subunit and can be divided into two subclasses, class 1A and B. While
class1A consists of an 85 kD regulatory subunit (p85) and a 110 kD catalytic
subunit (p110), class1B consists of only a 110 kD catalytic subunit
(p110γ/PI3Kγ). The class 1A PI3K pathway is activated either in one of two ways:
1) the p85 regulatory subunit binding to an activated tyrosine residue on the
activated interleukin (IL)-3 receptor, or 2) by the p110 subunit binding to activated
Ras. Once activated, PI3K translocates to the cell plasma membrane where it
phosphorylates the membrane phospholipid PI(4,5)P2 to produce PI(3,4,5)P3.
This in turn activates phosphoinositide-dependent protein kinase 1 (PDK1) and
facilitates its membrane localization where it phosphorylates and activates
protein kinase B (AKT), PI3K primary downstream effector protein.
Activation of PI3K/AKT survival pathway is essential to BCR-ABLmediated leukemogenesis [69] (Figure 9). BCR-ABL interacts indirectly with the
p85 subunit of PI3K through the adaptor molecules GRB-2 and SHC to stimulate
the constitutive activation of the p110 catalytic subunit [70]. This interaction is
mediated by BCR-ABL’s recruitment of GRB-2-associated binding protein
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(GAB2) through GRB-2. GAB2 then activates the p85 regulatory subunit of PI3K,
leading to constitutive AKT activation, which can also be achieved by SHC’s
binding to the SH2 domain within BCR-ABL’s carboxyl-terminus.
Mutations to the p85 subunit of PI3K resulted in the inhibition of BCR-ABLdependent growth in hematopoietic CML cells, which highlights the role of PI3K
in BCR-ABL-mediated pathogenesis [71]. Additionally, BCR-ABL upregulates the
transcription of the p110γ subunit of PI3K in several CML cell lines.
Constitutive activation of the PI3K/AKT pathway suppresses apoptosis in
several ways. AKT phosphorylates the pro-apoptotic protein, Bad, which is
scavenged by the cytosolic protein 14-3-3 and neutralized. This decreases
apoptosis by preventing Bad from binding and inhibiting the anti-apoptotic protein
Bcl-xL [72]. AKT promotes cell survival by phosphorylating and suppressing the
activity of FKHRL1/FoxO3, a member of the 14-3-3 Fork-head family of
transcription factors. Phosphorylation by AKT sequesters FoxO3 in the
cytoplasm, preventing it from translocating to the nucleus where it activates
genes necessary for cell death, such as Bad and Bim [73, 74]. AKT-induced
phosphorylation of the “initiator” death caspase, caspase-9, also decreases
apoptosis by inhibiting its proteolytic activities directly [75]. The ubiquitously
expressed serine/threonine kinase glycogen synthase kinase-3 (GSK-3), another
key downstream target of AKT, also induces apoptosis in tumor cells [76].
However, induction of apoptosis by GSK-3 is inhibited when it is phosphorylated
by AKT. Lastly, AKT activates the nuclear factor-kB (NF-kB) transcription-factor,
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which is involved in the transcription of anti-apoptotic genes. Normally NF-kB is
held in the cytoplasm in an inactive complex with its inhibitor, IkB. However,
phosphorylation of NF-kB by AKT releases the transcription factor and enables it
to perform its anti-apoptotic gene transcription [77].

Figure 9: BCR-ABL Activates the PI3K/AKT Anti-Apoptotic Signal
Transduction Pathway. By recruiting GRB-2-associated binding protein (GAB2)
or the adaptor molecule Shc, BCR-ABL activates the PI3K/AKT pro-survival
pathway; a process which can also be mediated by the signaling adaptor protein
Crk. This interaction facilitates PI3K/AKT –mediated anti-apoptotic signaling in by
phosphorylation and inhibition of: 1) the pro-apoptotic protein Bad, making it
incapable of suppressing the activity of Bcl-xL; 2) FKHRL1/FoxO3 , making it
incapable of translocating to the nucleus to activate pro-apoptotic proteins; 3) the
cysteine protease, caspase-9; 4) the serine/threonine kinase glycogen synthase
kinase-3 (GSK-3).
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The JAK/STAT Pathway
Signal transducer and activators of transcription (STATs) were originally
characterized as latent cytoplasmic transcription factors. They are members of a
family transcription factors that are involved in normal cellular response to
cytokines, such as cell differentiation. There are seven STAT proteins: STAT1,
STAT2, STAT3, STAT4, STAT5 (which consists of two closely related proteins,
STAT5A and STAT5B) and STAT6. They have diverse biological roles and
control critical cellular functions including cycle progression, cell proliferation,
survival, differentiation, apoptosis and oncogenesis.
STAT-mediated signal transduction occurs in several steps. Extracellular
binding of cytokines to their cognate receptors, followed by receptor dimerization,
leads to the engagement of associated Janus kinases (JAKs), a family of four
cytoplasmic non-receptor tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2), to the
receptors’ cytoplasmic tail. JAKs then become activated by auto-phosphorylation,
causing them to phosphorylate tyrosine residues within the receptor ‘s
cytoplasmic tails. These receptor-associated phosphotyrosine residues serve as
docking sites that recruit latent cytoplasmic STAT monomers through its SH2
domain. Further tyrosine phosphorylation by JAKs leads to activation of STAT
molecules, which in turn induces the formation of STAT homo- or heterodimers
through interaction of the phosphotyrosine of one molecule with the SH2 domain
of the other molecule. STATs can also be activated directly by growth factor
receptors, such as epidermal growth factor receptor (EGFR), platelet derived
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growth factor receptor (PDGFR) and GM-CSF receptor (or CD116), as well as by
cytoplasmic kinases and oncoproteins, such as SRC and ABL. Activated STAT
dimers are translocated into the nucleus via importin α/β as well as Ran-GDP.
Once inside the nucleus activated STAT molecules bind a unique cytokine
inducible sequence named GAS (γ-interferon activated sequences) within the
promoter of target genes, thereby activating gene transcription. The activation of
STATs is required for repopulation of the stem cell pool, as well as cell
proliferation and differentiation in response to external stimuli.
Several STATs, particularly STATs 1, 3 and 5, are constitutively activated
in several types of cancers. Typically STAT1 is involved in cell growth arrest [78,
79], in promoting apoptosis [80] and is implicated as a tumor suppressor [81].
STAT3 and STAT5 are involved in cellular transformation, cell cycle progression
and preventing apoptosis [82-84].
Aberrant activation of cytokine-mediated signal transduction pathways
involving STATs are capable of conferring cytokine-independent growth to
leukemia cells [85]. In CML, BCR-ABL can induce phosphorylation and activation
of STAT5 via its SH2 and SH3 domains, hijacking normal cellular functions by
circumventing the need for cytokine-mediated STAT5 activation. BCR-ABL
kinase-dependent STAT5 activation in CML cells has been shown to be an
essential component of CML’s pathogenesis [86, 87] (see Figure 10).
Cells with constitutive STAT activation promote malignant cell proliferation
by upregulating the gene expression cyclin D1, a cell cycle regulator that controls
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cell cycle progression from G1 to S phase, and c-Myc, a key transcription factor
that promotes cell cycle progression by inhibiting the expression of p21, a cyclindependent kinase inhibitor [88, 89]. c-Myc is also capable of upregulating the
expression cyclins. Additionally, constitutively activated STATs inhibits apoptosis
by upregulating the expression of members of the Bcl-2 family of anti-apoptotic
proteins Bcl-xL, Bcl-2 and Mcl-1 (see Table 4 for list of pro- and anti-apoptotic
Bcl-2 family of proteins).
The combined effects of 1) deregulated cell cycle progression and, 2)
reduced apoptosis, results in uncontrolled cell proliferation and malignant cell
transformation characteristic in CML pathogenesis.

The BCL-2 Family of Proteins. The Bcl-2 (B-cell lymphoma-2) family of proteins
governs mitochondrial outer membrane permeability (MOMP). They are
categorized functionally by their ability to promote or inhibit cell death (pro- or
anti-apoptotic) and structurally by their Bcl-2 homology (BH) domains. Each
protein possesses at least one of four of the characteristic BH domains, named
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BH1-4, and can therefore be subdivided further into those that have multidomain
and those that have BH3-only domain. With the exception of Mcl-1 and BLF/A1,
which have three conserved BH domains, the anti-apoptotic family of proteins
possesses all four domains. Conversely, with the exception of Bax, Bak and Bok
which are multidomain proteins, all the pro-apoptotic family of proteins are BH3only domain-containing proteins. TM, transmembrane.
Decreased Adhesion to Bone Marrow Stroma and Extracellular Matrices
During hematopoiesis, cell differentiation and proliferation is tightly
regulated through specific interactions between HSCs and bone marrow stroma.
Transformed CML progenitor cells escape normal negative regulatory signals
and exhibit enhanced motility and perturbed adhesion properties. Rho GTP
activating proteins (GTPases) are important regulators of cell motility, cell
adhesion, actin assembly and cell migration [90]. They play important roles within
the cell by transducing extracellular regulatory signals to effector molecules
(reviewed in [91]. Rac GTPases, Rac 1-3, are members of the Rho GTPase
family and cycle between GDP- and GTP-bound states. BCR-ABL activates
RhoA and Rac1 GTPases via BCR’s Rho/GEF domain and ABL’s Rac GAP
domain respectively. Additionally, Rac1 and Rac2 are significantly upregulated in
CD34+ chronic phase CML cells [92].
BCR-ABL recruits and activates Rac1 through its interaction with its
hematopoietic-specific GEF, Vav, which leads to alternations in actin assembly.
Deregulation of actin assembly enhances the motility of CML cells and facilitates
their diminished adhesion to bone marrow stroma [93]. CML cells also display
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increased expression of focal adhesion proteins, such as focal adhesion kinase
(FAK), talin and paxillin, when compared to normal cells. These focal adhesion
proteins play important roles in cell motility and survival, and their increased
expression enable CML cells to escape the normal negative regulatory signals
provided by component of the BME [94]. Additionally, CML cells express an
adhesion-inhibitory variant of β1 integrin that is not found in normal progenitor
cells [95].
Taken together, BCR-ABL-mediated cytoskeletal rearrangement
contributes to CML pathogenesis.

Figure 10: Summary of Signal Transduction Pathways Activated in BCRABL-Mediated Leukemogenesis. BCR-ABL is capable of phosphorylating
numerous substrates to activate signal transduction pathways shared by cytokine
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receptors and are involved in the growth and differentiation of hematopoietic
cells. These activated signal transduction pathways include: Ras/MEK, which
results in promitotic transcriptional gene regulation; PI3/AKT; which results in
suppression of apoptosis; JAK/STAT5, which results in pro-survival gene
transcription; Rac-GTPase activation, which results in cytoskeletal reorganization
and anchorage-independent growth.
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CHAPTER IV
TREATMENT FOR CHRONIC MYLOID LEUKEMIA

Before Signal Transduction Inhibitors
Prior to the development of targeted therapy against CML, therapeutic
options included cytotoxic drugs such as busufan, hydroxyurea, recombinant
interferon α (rIFNα), bone marrow transplant (BMT) and allogeneic stem cell
transplantation (allo-SCT).
Busulfan
Busulfan is an inexpensive, oral alkylating agent that produces DNAcrosslinks resulting in the inhibition of DNA and protein synthesis. It produces
periods of hematologic response in patients and is often restricted to those who
are intolerant or resistant to hydroxyurea (see Table 5 for a list of definitions of
the types of response to CML treatment). While it lowers white blood cell (WBC)
count, its myelosuppressive effects were often delayed and persistent, which
complicated therapy. Additional draw-backs to using busulfan include
hyperpigmentation and interstitial lung disease [96, 97].
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Hydroxyurea
Hydroxyurea is also a DNA-synthesis inhibitor that achieved hematologic
remission in patients within 1-2 months of use and is normally well tolerated in
CML patients. Although it has been shown to be better than busulfan, both drugs
rarely induced cytogenic responses. Neither busulfan nor hydroxyurea prevented
disease progression from chronic phase to acute phase in CML patients.
Recombinant Interferon-Alpha
Recombinant interferon-alpha (IFNα) treatment produces cytogenetic
response in 70% of patients, with 20% of those patients experiencing complete
cytogenic response. Studies show that rIFNα works well against CML alone or in
combination with cytarabine, another DNA-damaging agent. It increased patients’
survival rates and is the treatment of choice for patients who do not have a HLAmatched bone marrow donor or are too old for BMT [98, 99]. Under rIFNα
treatment patient survival at 5 years was 57%, compared to 42% in the other
previously discussed treatment groups (CML Trailists’ Coorperative Group, J Nat
Cancer Inst. 1997; 89:1616-1620). Unfortunately, rIFNa treatment is limited by its
toxicity profile, with 15-25% of patients discontinuing treatment due to intolerable
side effects and another 35-50% requiring dose reduction due to poor drug
tolerance. Side effects include anorexia, fever, chills and postnasal drip.
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Allogeneic Stem Cell Transplantation
At present, only allogeneic stem cell transplantation (allo-SCT) is an
effective and curative treatment option for CML patients, providing long-term
disease eradication [100]. Stem cells are derived from the bone marrow or
peripheral blood of donors. Results are best for patients in chronic phase when
compared to those in accelerated or blast crisis phase. The long term survival
rate using this treatment method is 50-60% for CML chronic phase patients, 1520 for accelerated phase patients, and <10% for blast crisis phase patients [101].
Treatment-related morbidity and mortality rates in allo-SCT patients are
high and often associated with organ toxicity, complications from infection and
chronic graft-versus-host disease (GVHD) [102]. Due to the difficulty in finding a
healthy, young HLA-matched sibling or donor, allo-SCT is often reserved for
patients under the age of 55 years old who are unresponsive to secondary BCRABL inhibitors.
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Rationally Designed BCR-ABL Signal Transduction Inhibitors
Imatinib Mesylate
Constitutive BCR-ABL kinase activity in HSCs is an essential component
of CML pathogenesis. The identification of BCR-ABL as the hallmark oncogenic
transforming protein in CML made it an ideal target for drug development. This
gave rise to rationally designed, small bioavailable signal transduction inhibitors
(STI) specific for the tyrosine kinase domain of BCR-ABL. Imatinib mesylate
(imatinib, also known as Gleevec; formerly STI571 and CGP 57158; Novartis
Pharmaceuticals Corporation, Basel, Switzerland) was identified as a lead
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compound in a high throughput in vitro screening for tyrosine kinase inhibitors
(TKIs). The 2-phenylaminopyrimidine-derivative was designed to bind the ATP
binding site of ABL kinases (see Figure 11) While imatinib is also capable of
binding to other kinases, such as the stem cell factor (SCF) cytokine receptor, ckit, and platelet-derived growth factor receptor (PDGFR), it is specific for ABL
oncoproteins, including c-ABL and ETV1-ABL.
Functionally, imatinib easily transverses the cell membrane and selectively
binds the tyrosine kinase domain of BCR-ABL. This domain consists of a bi-lobed
structure in which Mg-ATP is located in a deep cleft between the amino- and
carboxyl-terminal lobes. BCR-ABL cycles between two distinct active and
inactive states, acting as a “molecular switch” depending on the conformation of
its activation loop which contains the highly conserved asparaginephenylalanine-glycine (DFG) motif.
In an active kinase conformation, Y1294 in the activation loop becomes
phosphorylated and takes on a ‘DFG-out’ configuration, in which these
conserved residues are flipped out of their usual position. This open
conformation provides a platform for substrate binding and activation.
However, in the inactive kinase conformation, this DFG motif is folded into
the ATP-binding site and makes a channel opening outside the threonine 315
gatekeeper residue [103]. This residue is essential as it is located near the ABL
catalytic domain in the middle of the imatinib binding site and controls access to
the hydrophobic region of the enzymatic active site. The inactive conformation of
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BCR-ABL causes an auxiliary binding site within the ATP-binding pocket to open,
which facilitates imatinib binding by the formation of hydrogen bonds. Interaction
with imatinib traps and stabilizes BCR-ABL tyrosine kinase in an inactive,
“closed” conformation, which terminates its kinase activity and inhibits its autoand substrate phosphorylation [104].
With has an IC50 value of 0.5 µM, imatinib has been shown to induce
apoptosis in BCR-ABL+ cell lines as well as in primary leukemia cells from CML
patients [105] (see Table 6 for a profile of BCR-ABL inhibitors). Cells undergo
apoptosis within 48 to 72 hours following imatinib treatment.
Chronic phase CML patients who had failed rIFNα-therapy and were
treated with 400 mg/day of imatinib did not progress to accelerated or blast crisis
phase. Additionally, 95% of achieved complete hematologic response and 60%
had a major cytogenic response (MCR). A long-term follow-up of these patients
showed a 13% increase in the MCR rate to 73%, with 63% of patients having a
CCR. Studies done in accelerated-phase CML patients were encouraging,
though less dramatic. Eighty two percent of these patients showed hematologic
responses, with MCR seen at 24% and CCR at 17%.
Imatinib’s efficacy has revolutionized CML patient care ([104, 106]. By
obstructing BCR-ABL’s tyrosine kinase domain and its ability to commandeer
signal transduction pathways crucial for CML pathogenesis, imatinib inhibits
BCR-ABL’s role in cell transformation at micromolar concentrations.
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Yet despite the efficacy of imatinib, CML patients in advanced stages of
the disease (whose in accelerated or blast crisis phase) eventually display
inadequate responses to treatment and often experience relapse within a year
[107].
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Figure 11: Mechanism of Imatinib Action in Chronic Myeloid Leukemia
Cells. (A), CML pathogenesis is mediated by the constitutive activation of the
BCR-ABL oncoprotein, which binds ATP to phosphorylate and activate numerous
substrates involved signal transduction and malignant cell transformation. (B),
Chemical formula of imatinib (STI-571). (C), Imatinib works as a competitive
inhibitor and ATP-mimic that selectively competes for and binds to the ATP
binding site/tyrosine kinase (TK) domain of BCR-ABL. (D), Ribbon representation
of the three dimensional crystal structure of the catalytic domain of the ABL
tyrosine kinase in complex with imatinib (figure taken from Wikimedia Commons).
Imatinib Resistant Chronic Myeloid Leukemia
In vitro resistance models have played a critical role in identifying various
mechanisms of primary (acquired) resistance that thwart the effects of imatinib
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treatment. Patient relapse is associated to three main mechanisms of imatinib
resistance: 1) point mutations within BCR-ABL’s tyrosine kinase domain that (a)
directly interfere with the ability of imatinib to bind to BCR-ABL kinase domain, or
(b) impair the ability of BCR-ABL to achieve the inactive conformation required
for imatinib binding [108-111]; 2) bcr-ABL gene amplification, and 3)
overexpression of drug transporters.
Point Mutations within the BCR-ABL Kinase Domain
Gorre et al. was the first to demonstrate the relationship between a point
mutation at ABL kinase domain and imatinib resistance [108]. The most resistant
kinase mutation occurs when threonine 315 gatekeeper residue changes to
isoleucine (T315I). This change directly blocks the ability of imatinib to bind the
kinase domain while still retaining BCR-ABL’s capacity to bind ATP and catalyze
substrate phosphorylation. The T315I point mutation causes a shift in the
equilibrium between BCR-ABL’s inactive and active states, restoring BCR-ABL
kinase activity. This can be attributed to T315I-mutation-specific changes in
phosphorylation pattern within the kinase domain. This mutation results in a shift
in the phosphorylation of two key tyrosine residues within the ATP binding loop
that confers an oncogenic fitness advantage to cells possessing this mutation
[112].
Imatinib mesylate resistance is commonly associated with mutations that
alter the flexibility of the BCR-ABL kinase domain to adopt the inactive
conformation needed for imatinib binding. A summary of some of these well-

42

characterized mutations is provided in Table 7. Like T315I, these mutations result
from amino acid substitutions and consist of approximately 25 amino acids
residues distributed throughout the ABL kinase domain that provide varying
degrees of imatinib resistance. In some patients with stable chronic phase CML a
number of these mutations are associated with disease progression to advanced
stages [113]. The most commonly characterized mutations that account for 60–
70% of all kinase mutations affect residues Gly250, Tyr253, Glu255, Met351 and
Phe359.
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BCR-ABL Gene Amplification
Gene amplification of target proteins is often characteristic of malignant
cell transformation and is a frequently used mechanism to generate drug
resistant neoplastic cells. Studies show that resistance to imatinib also occurs
through BCR-ABL gene amplification. Imatinib-resistant CML cells have
displayed higher levels of BCR-ABL protein expression and phosphorylation
when compared to parental, imatinib-sensitive cells due to robust overexpression
of BCR-ABL mRNA transcripts [114]. Studies also show BCR-ABL gene
amplification linked to the presence of additional copies of the gene in some CML
patients [115]. In other patients, unusual karyotyping using banding cytogenetics
coupled with the overexpression of BCR-ABL led to the discovery of multiple
double minutes , which are small fragments of extrachromosomal DNA encoding
the BCR-ABL gene [116] (Figure 12).
Disease progression from chronic to accelerated or blast crisis phase in
CML patients is associated with an increase in BCR-ABL transcripts during
imatinib treatment [108, 117]. This increase in transcripts correlates with
enhanced CML cell survival determined by their ability to overcome the apoptotic
effects of imatinib. These results underscore the fact that BCR-ABL gene
amplification is an important mechanism of acquired resistance to imatinib.
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Figure 12: Gene Amplification Due to the Presence of Double Minutes. FISH
showing cells in metaphase. Chromosomes stained in red and double minutes
stained in green (left) and all nuclear DNA stained black (right). In both panels,
the double minutes are indicated by arrow. Image taken from Wikipedia. This
work is in the public domain in the United States because it is a work of the
United States Federal Government.
Overexpression of Drug Transporters
Cancer cells exposed to chemotherapeutic agents for an extended period
of time often develop a multidrug resistance (MDR) phenotype that is
characterized by overexpression of the multidrug resistance1(MDR1; also called
P-glycoprotein (P-gy), ABCB1 and CD243) efflux pump. The broad substrate
specificity of MDR1 enables it to regulate the distribution and bioavailability of
numerous drugs. In CML patients this results in an excessive efflux of imatinib,
rendering the chemotherapeutic agent ineffective.
The importance of MDR1 in imatinib resistance is reflected in one recent
study that demonstrated that polymorphisms of the MDR1 gene are indicative of
the type of molecular response CML patients may have to imatinib treatment

45

[118]. MDR1. Retroviral-mediated transfection of BCR-ABL+ cells with the MDR1
gene greatly decreased its sensitivity to the apoptotic effects of imatinib, a
phenotype that was could be reversed with the addition of MDR1 pump
modulators [119]. Additionally, cell lines resistant to imatinib were capable of
growing continuously in its presence due to increased expression of the MDR1
gene. Furthermore, Dulucq et. al. also revealed that the presence of MDR-1
polymorphisms correlated to suboptimal patient response to imatinib treatment
[118]. Similarly, patients with CML and treated with high dose imatinib displayed
drug clearance and drug resistance in a manner consistent with MDR1-mediated
elimination [120].
Nilotinib
The need to address imatinib-resistant CML ushered in an active area of
research focused on the development of second generation inhibitors. The
observation that imatinib-resistance is predominantly associated with mutations
within BCR-ABL kinase domain led to the development of other small-molecule
ABL kinase inhibitors with less stringent binding requirements and that are more
effective in combating resistance.
One such inhibitor is nilotinib (AMN107, Novartis Pharmaceuticals
Corporation, Basel, Switzerland) (AMN107; Novartis), another
phenylaminopyrimidine derivative that followed a rational drug design based on
the crystal structures of imatinib in complexes with ABL. It was developed by
modifying the N-methylpiperazine ring within the imatinib molecule. This
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modification facilitates greater hydrogen-bond interactions with wild-type and
many imatinib-resistant kinase mutants by providing a better topological fit to the
kinase domain. Clinical studies show that nilotinib is active against 32 of the 33
mutant forms of BCR-ABL [121, 122]. It is approximately 30-fold more potent
than imatinib as an ABL inhibitor, with an IC50 value of 30 nM. However, like
imatinib, it possesses no significant activity against the T315I mutant protein.
Nilotinib is effective in patients who are unresponsive to treatment with
imatinib. When CML patients in accelerated-phase were treated with nilotinib
they experienced a hematologic response rate of 47% and a MCR rate of 29%,
with a 12-month survival rate of 79% [123]. Clinical studies show that nilotinib is
also well-tolerated at doses of up to 600 mg daily [124].
Dasatinib
The need to address imatinib-resistant CML also resulted in the
development of dasatinib (BMS-354825; Bristol-Myers Squibb), a dual BCRABL/SRC family kinase inhibitor (SFK: Fyn, Yes, SRC, Lyn, Lck, Fgr, Blk, Hck). It
also has additional activity against c-Kit and PDGFR. Dasatinib is clinically more
active than imatinib and nilotinib against both wild-type and mutant BCR-ABL
proteins responsible for drug resistance [121, 125].
Dasatinib has less stringent conformational requirements for interaction
with BCR-ABL kinase domain than nilotinib. Consequently, it binds both the
active and inactive conformations. Dasatinib induces complete hematologic
remissions and major cytogenetic responses in imatinib-resistant CML patients in
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all three phases, chronic, accelerated, and blast phases. Response rates show
that 95% of patients with chronic-phase CML and 82% of patients in acceleratedphase CML respond to dasatinib treatment during a >12 months median followup timeframe [126]. However, like imatinib and nilotinib, dasatinib has no effect
against the T315I mutation and nearly all blast crisis phase patients experience
relapse in less than a year of treatment
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CHAPTER V
MINIMAL RESIDUAL DISEASE CHRONIC MYELOID LEUKEMIA

Despite the efficacy of imatinib, nilotinib and dasatinib in achieving high
rates of cytogenetic and hematological responses to varying degrees, they are
unable to override all forms of drug-resistant kinase mutations. Overtime some
CML patients, particularly those in advanced stages of the disease, become
refractory to further treatment. In almost all patients the BCR-ABL transcript
persists below the level of cytogenetic detection while undergoing treatment,
indicating the presence of minimal residual disease (MRD) CML. This suggests
that treatment with imatinib and more potent BCR-ABL inhibitors is not sufficient
to eradicate this disease.
Several factors have been implicated in contributing to MDR CML: 1) the
failure to kill leukemic stem cells, 2) BCR-ABL gene amplification, 3) the
presence of pre-existing BCR-ABL kinase mutations, 4) epigenetic changes, and
5) the tumor microenvironment.
Failure to Kill Leukemic Stem Cells
The identification of a rare population of primitive quiescent BCR-ABL+
cells with an intrinsic insensitivity to imatinib treatment lends support this model
[127-129]. In vitro studies of quiescent CD34+ leukemic cells revealed that they
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were resilient against high-dose imatinib treatment of up to 10-folds higher than
the normal dosage. Additionally, while imatinib suppressed the proliferation of
leukemic colony-forming cells (CFCs) and long-term culture-initiating cells (LTCICs) it did not induce apoptosis in these primitive cells.
Furthermore, residual BCR-ABL+ stem cells persisted in the bone marrow
of CML patients who had achieved CCR with imatinib. This indicates that
primitive BCR-ABL+ CML cells that are capable of entering the cell cycle could
repopulate the bone marrow compartment to facilitate patient relapse when
imatinib is withdrawn.
The insensitivity of leukemic stem cells to the apoptotic effects of imatinib,
coupled with their self-renewing capacity are important contributing factors to
MRD CML.
Pre-existing Mutations within the BCR-ABL Tyrosine Kinase Domain
In one study 12% of CML patients who had no cytogenetic response to
imatinib therapy and who did not display bcr-ABL gene amplification possessed
rare cells that had point mutations within the kinase domain at the time of
diagnosis. This included the highly resistant Thr315Ile mutation [130].
Additionally, BCR-ABL+ imatinib-naive cells from CML patients possessed the
Glu255Lys point mutation, which is involved in preventing the BCR-ABL kinase
from adopting the inactive conformation needed for imatinib interaction [131].
Pre-existing mutations in BCR-ABL+ cells could facilitate their outgrowth
during therapy owing to the selective pressure of imatinib. The ‘fitness’
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advantage conferred to these mutated cells would enable a clonal selection of
the minor population of cells carrying the mutation.
Epigenetic Contributions
While the t(9;22) translocation that produces the BCR-ABL oncogenic
tyrosine kinase is the major transforming even in CML, additional molecular
and/or epigenetic changes have been implicated in CML oncogenesis. These
changes are also associated with the transition from chronic to blast crisis phase
that accompanies the emergence of MRD CML and patient relapse.
Disease progression in CML patients has been linked to increase de novo
DNA-methylation of the ABL promoter contained within a CpG island, which is
associated with ABL gene silencing [132, 133]. This suggests that the course of
the disease may be documented by the extent of CpG methylation.
During chronic phase CML the expanded granulocytic lineage still retains
its ability to differentiate. However, the accelerated and blast crisis phases are
characterized by decreased cell differentiation and the subsequent accumulation
of immature hematopoietic cells. Molecular changes resulting in differentiation
arrest are associated with this transition. Gain-of-function mutations in GATA-2, a
gene that serves as a negative regulator of hematopoietic stem progenitor cell
differentiation, resulted in its enhanced transactivation capacity and augmented
inhibition of hematopoietic cell differentiation [134].
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Tumor Microenvironment
The bone marrow microenvironment (BME) provides CML cells direct
interaction with stromal cells and extracellular matrices (ECM), which may
modulate drug response. We reported previously that adhesion to fibronectin was
sufficient to protect K562 CML cells from imatinib-induced cell death (Damiano
[135, 136]. Similar studies reveal that direct contact of leukemic cells with the
human stromal cell line, HS-5, significantly increased cell proliferation, viability
and colony formation [137]. Additionally, leukemic-stromal cell interactions
enhanced in vitro leukemic cell survival while attenuating chemotherapy-induced
cell killing. Using a co-culture model consisting of leukemic cells and bone
marrow-derived stromal cells, studies show that this interaction resulted in
increased activation of the several signal transduction pathways involved in cell
survival, including PI3K/AKT, Ras/ERK and STAT3 [138].
The BME is also a rich source of cytokines and growth factors that could
also influence drug response. While the retroviral transduction of BCR-ABL into
severe combined immunodeficient (SCID) bone marrow progenitor cells grown
healthy mice resulted in rapid, fatal, imatinib-resistant leukemia, its transduction
into similar cells lacking the cytokine receptor common γ-chain resulted in
imatinib-sensitivity. This suggests that cytokines within the microenvironment are
responsible for conferring imatinib resistance [139]. Studies to identify cytokines
involved in modulating imatinib sensitivity revealed that autocrine secretion of
GM-CSF was involved. Its secretion activates the JAK/STAT5 pathway and
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protects imatinib-naive and CML progenitor cells from death induce by BCR-ABL
inhibitors [140]. Additionally, mutated CML cells were able to spread resistance
to non-mutated cells through overexpression of IL-3, which resulted in the
activation of the Ras/MEK and JAK2/STAT5 signal transduction pathways [141].
This highlights the importance of the bone marrow microenvironment in
modulating imatinib response. This resistance can be conferred by either direct
adhesion to bone marrow stroma or by the secretion of bone-marrow derived
soluble factors.
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CHAPTER VI
THE ROLE SIGNAL TRANSDUCERS AND ACTIVATORS OF
TRANSCRIPTION (STATS) IN CHRONIC MYELOID LEUKEMIA
ONCOGENESIS AND DRUG RESISTANCE

Receptor engagement by hematopoietic cytokines results in their
phosphorylation and the activation of JAKs. These receptors consist of a unique
ligand-binding subunit and a signal transducing subunit [142] (see Figure 13 for
cytokine receptor families). STATs are activated transiently by numerous
cytokines via JAKs [143], as well as SFKs [144].
Various types of hematologic malignancies are associated with the
aberrant, constitutive, cytokine-mediated activation of STAT proteins. In CML,
BCR-ABL activates signal transduction pathways shared by many hematopoietic
cytokines, including the STAT3 and STAT5 signaling pathways.
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Figure 13: Cytokine-Receptor Families. Cytokine-receptors consist of a ligandbinding subunit and a signal-transducing subunit. Hematopoietic cytokine
receptors can be categorized based on their signaling subunit as follows: 1)
those that signal through a single subunit, which includes growth hormone (GH),
prolactin (PRL), erythropoietin (EPO); granulocyte colony-stimulating factor (GCSF), and thrombopoietin )THPO); 2) those that signal through the gp130 or gp
130-related subunit, which includes interleukins (IL)-6, 11 and 12, leukemia
inhibitory factor (LIF), oncostatin M, ciliary neurotrophic factor (CTNF), and
cardiotropin-1 (CT-1); 3). those that signal through the gp140β-subunit or a
ligand-binding α subunit, which includes IL-3 and 5, and granulocyte-macrophage
colony-stimulating factor (GM-CSF); 4) those that signal through a common γchain (γC) and a α or β ligand-binding subunits, which includes IL-2,4,7,9, and 15;
5) those that signal through two more subunits, such as the interferon-γ (IFN-γ)
subfamily of receptors, which includes IFNRI and II.
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The Role of STAT3
STAT3 governs signal transduction in growth factor-mediated control of
hematopoiesis and myeloid cell differentiation. Its activation up-regulates the
expression of genes associated with cell survival and proliferation including Bcl-x,
Mcl-1, and cyclin D1 [89, 145, 146]. Persistent STAT3 activation has been
detected in a variety of hematopoietic malignancies and solid tumors [147-149].
The enforced expression of BCR-ABL in primitive embryonic stem cells (ESCs)
resulted in their persistent STAT3 activation and caused the cells to retain their
primitive morphology by inhibiting their differentiation [150]. The increased
activation of STAT3 in primary leukemia blast cells lends support to its
involvement in disease progression of CML patients and their’ transition from
chronic phase to blast crisis phase [151].
Taken together, these observations highlight the role of amplified STAT3
activation in the pathogenesis of CML and underscore its involvement in imatinib
resistance.
The Role of STAT5
STAT5 has gained prominence because it is often constitutively activated
in a wide variety of human cancers, ranging from solid tumors seen prostate,
lung, breast and colon cancers, to hematologic malignancies, such as
myeloproliferative disorders [152-155]. It is activated by non-receptor tyrosine
kinases, such as BCR-ABL and SFKs. Like STAT3, STAT5 activation upregulates the expression of Bcl-x, Mcl-1, and cyclin D1.
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BCR-ABL-dependent STAT5 activation was observed in several leukemic
cell lines possessing the Ph+ clone, but not untransformed cells or BCR-ABLnegative leukemia cells [154, 156]. Furthermore, the expression of BCR-ABL in
IL-3/GM-CSF-dependent leukemic cells resulted in aberrant STAT5 activation
and growth factor independence [157]. Similarly, constitutive activation of STAT5
by the SFK, Hyk, resulted in cytokine-independent cell growth in cytokinedependent leukemic cells [158]. STAT5 activation is also associated with chronicto-blast crisis phase transition in leukemia patients. As indicated previously, in up
to 95% of AML blast cells constitutive activation of STAT3 and STAT5 could be
detected [151].
Interestingly, increased STAT5 activation in BCR-ABL-positive leukemic
cells and STAT5’s ability to confer resistance to dasatinib has been shown to be
directly correlated with leukemic cell density [159]. This recent study revealed
that an increase in the density of leukemic cells resulted in a decrease in
dasatinib’s efficacy against STAT5-mediated signaling. Results indicate that this
observation may attribute to the upregulation of STAT5-regulated anti-apoptotic
proteins.
Taken together, this demonstrates that constitutive STAT5 activation
promotes CML pathogenesis and imatinib resistance by up-regulating the
expression of anti-apoptotic proteins, Bcl-x, Mcl-1 and cyclin D1. Additionally,
enhanced STAT5 activation is capable of mediating cytokine-independent growth
in leukemic cells, leading to increased cell survival.
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CHAPTER VII
OBJECTIVES

The BCR-ABL fusion gene is critical for the development of CML.
Treatment with imatinib is highly effective against CML; however treatment
response in patients is compromised by the emergence of imatinib resistance. In
vitro resistance models often fail to consider the role of the tumor
microenvironment in the emergence of imatinib resistance. The predominant
microenvironment of CML is the bone marrow, a rich source of both soluble
factors and extracellular matrixes which may influence drug response. This study
was developed to address the influence of the bone marrow microenvironment
on imatinib sensitivity. We utilized an in vitro co-culture bone marrow stroma
model to demonstrate that stable soluble factors secreted by the HS-5 human
bone marrow stroma cell line were sufficient to protect K562 CML cells against
imatinib-induced cell death. Subsequently, we observed that HS-5-derived
conditioned media (CM) also provided protection against cell death. Previous
studies showed that HS-5 stromal cells secrete cytokines and growth factors
involved in the growth and differentiation of hematopoietic stem cells [160]. Some
of these cytokines are capable of activating signal transduction pathways
involved in myeloid differentiation. Investigations into the activation of survival
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pathways that reconstitute BCR-ABL signaling in CM may provide novel insights
into the mechanism of environment-mediated drug resistance (EMDR). One such
pathway being investigated is the signal transducer and activator of transcription
3 (STAT3) survival pathway. A review of the current literature led to the following
hypothesis:
Bone marrow-derived soluble factors in conditioned media contribute to
the failure of BCR-ABL inhibitors to eradicate minimal residual disease
CML.
In order to refute or support this hypothesis, the following objectives were
formulated:

1. To determine if HS-5-derived CM protects CML cell lines from death
induced by second generation BCR-ABL inhibitors
2. To determine whether HS-5-derived CM increased the proliferation and
clonogenic survival of CML cells
3. To determine whether HS-5-derived CM mediate the activation of STAT3
and STAT5 cell survival pathways in CML cells
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CHAPTER VIII
MATERIALS AND METHODS

Cell Cultures
Human CML K562 and KU812 cells (obtained from the American Type Culture
Collection) were cultured in RPMI 1640 supplemented with 10% fetal bovine
serum, 1% L-glutamine, and penicillin/streptomycin [regular medium (RM); Life
Technologies] at 37°C in 5% CO2 in a humidified incubator. The human stromal
cell line HS-5 (also obtained from the American Type Culture Collection) was
maintained under the same conditions.
Generation of Conditioned Media (CM)
CM was generated by culturing 5 x 105 HS-5 cells/mL in RM overnight in a
humidified atmosphere at 37°C with 5% CO2 to achieve 75% to 80% confluency.
Subsequently, the medium was removed and the cells were incubated in fresh
medium for 3 hours. The supernatant was then collected and cleared of
contaminating cells by centrifuging at 2,000 rpm for 5 minutes. Supernatant was
aliquoted and stored at -80°C for future use.
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Drugs and Reagents
Imatinib mesylate and nilotinib (AMN107), supplied by Novartis Pharma, were
dissolved in DMSO as a 10 mM stock solution and stored in aliquots at -20°C.
Dasatinib, supplied by Bristol-Myers Squibb, was treated similarly.
Treatment with Tyrosine Kinase Inhibitors
Preparation of Lysates and Western Blotting
K562 or KU812 cells were cultured at a density of 4 x 105/mL in either RM or CM
for various time points in the presence or absence of either a matched vehicle
control (DMSO) or drug (imatinib or dasatinib). Subsequently, cells were pelleted
and lysed in radioimmunoprecipitation assay lysis buffer supplemented with
phosphatase and protease inhibitors (1 mM Na3VO4, 1 mM NaF, 1 mM
phenylmethylsulfonyl fluoride, 10 µg/mL leupeptin, and 10 µg/mL aprotinin).
Insoluble materials were removed by centrifugation at 4°C for 20 minutes at
15,000 rcf . Antibodies used for Western blotting were anti-STAT3, anti-STAT3
(Tyr705), anti-Bcl-xl, anti-Mcl-1, anti-Survivin, and p-SRC (all from Cell Signaling
Technologies).
Apoptosis Assay
Apoptosis was measured using the Annexin V-FITC apoptosis detection kit
(Alexis Biochemicals) according to the manufacturer’s recommendations. Data
were acquired using CellQuest Pro software version 4.0.2 (BD Biosciences) and
analyzed using FlowJo software version 7.2.2 (Tree Star).
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siRNA Transfection
K562 cells cultured in RM were transiently transfected with either STAT3 siRNA
(siGENOME ON-TARGETplus SMARTpool reagent; Dharmacon) or a control
siRNA (ONTARGETplus siCONTROL Nontargeting reagent; Dharmacon) using
Amaxa Nucleofector methodology (Amaxa). Briefly, 1 x 106 K562 cells were
transfected per manufacturer’s instructions. Thirty-six hours post-transfection, the
process was repeated to ensure continued suppression of STAT3 levels.
Transfected K562 cells (2.0 x 105/mL) were then cultured in RM or CM for 3
hours then treated with 250 nM imatinib or a vehicle control (DMSO). Cell death
was measured using Annexin V apoptosis assay as described previously.
Bromodeoxyuridine (BrdU) Antibody Staining
2.5 x 105 K562 cells/mL were cultured in RM or CM for 24 hours then pulsed with
30 µg/mL 5-bromo-2-deoxyuridine (BrdU) for 30 minutes. Cells were fixed with
ethanol and BrdU incorporation was detected using FITC-conjugated anti-BrdU
antibody (Calbiochem, Gibbstown, NJ). Data acquisition and analysis were done
using fluorescence-activated cell sorting (FACS).
Clonogenic Assay
K562 cells were diluted to a concentration of 10,000 cells/mL in RM or CM for 6
hours in the absence or presence of imatinib and incubated at 37°C with 5%
CO2. Cells are transferred to 0.3% final agar solution reconstituted in RM or CM.
Once the agar solidifies, cells were allowed to incubate for 8-10 additional days.
Cell colonies (>50 cells) were then counted on 2 mm grid culture dish (Corning).
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Preparation of Nuclear Extracts
Nuclear extracts were prepared by resuspending 5 x 106 K562 cells in hypotonic
buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol,
0.2 mM PMSF, 2 µg/mL leupeptin, 0.15 µg/mL aprotinin) followed by incubation
on ice 5 minutes. Cells were centrifuged for 10 seconds at 14000 rpm and
washed once with hypotonic buffer. The nuclei were collected by centrifugation
for 5 minutes at 14000 rpm and washed once with hypotonic buffer. The nuclear
pellet was resuspended in 50 µL of hypertonic buffer (20 mM HEPES-KOH, pH
7.9, 25% glycerol, 450 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
dithiothreitol, 0.5 mM PMSF, 2 µg/mL leupeptin, 0.15 µg/mL aprotinin), incubated
for 30 minutes at 4ºC followed by centrifugation for 2 minutes at 14000 rpm.
Electrophoretic Mobility Shift Assay (EMSA)
A total of 2 µL nuclear extract was incubated with a double-stranded 32P-labeled
oligonucleotide (1 ng) sis-inducible element (SIE), (5’TCGAGTATTTCCCAGAAAAGGAACAGCT-3’ and its complement) in 10 µL
binding buffer (25 mM HEPES, pH 7.9, 100 µM ethylene glycol tetraacetic acid
(EGTA), 200 µM MgCl2, 500 µM dithiothreitol, 1 µg/mL BSA, 0.2 µg/mL poly
dI:dC) for 15 minutes at room temperature. Protein-DNA complexes were
detected by autoradiography and quantified using a phosphoimager.
MTT Assay.
Incubate 50,000 K562 cells/ mL for 3 hours in either regular media or conditioned
media. Add varying concentrations of imatinib. Incubate drug-treated cells for 72
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hours at 37°C, 5% CO2. Add MTT dye and incubate for 3 hours at 37°C, 5% CO2.
Read absorbance at 540 nm on a spectrophotometer.
Statistical Analysis
A preliminary examination of the data was done using descriptive summary
analysis and the Anderson-Darling statistic. Significance testing of the doseresponse apoptosis assays was done using analysis of covariance. The
Student’s t test was used for the siRNA experiments to compare the logtransformed fold change values, with the null hypothesis being a log (fold
change) = 0 (or conversely the fold-change = 1). A significance level of 0.05 was
considered statistically significant for all tests. The geometric means of the four
ratios for siRNA experiments and the 95% confidence intervals were also
calculated
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RESULTS

Co-culture Bone Marrow Stromal Model Protects K562 CML Cells from
Imatinib-Induced Apoptosis
Previous work done by Torok-Storb et. al. revealed that HS-5 human
stromal cells are capable of producing cytokines and growth factors that are
involved in the growth and differentiation of HSC and are also capable of
supporting the ex vivo expansion of both immature and mature progenitor cells
[160]. To test our hypothesis that the bone marrow microenvironment contributes
to the failure of BCR-ABL inhibitors to eradicate minimal residual disease CML,
we utilized a co-culture bone marrow microenvironment transwell model system
and took advantage of HS-5 stroma cells’ ability to support HSC and their
progenitors. We wanted to determine whether the bone marrow
microenvironment protects the K562 CML cell line, which originated from the
pleural effusion of a CML female patient in terminal blast crises phase, from
death induced by imatinib.
Using this co-culture model, we first wanted to delineate the contributions
of (1) HS-5-derived soluble factors alone, and (2) direct adhesion to HS-5 cells
on imatinib resistance in K562 CML cells treated with 1 µM of imatinib (Figure
14). Our control samples consisted of K562 cells cultured in regular media (RM).
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Here we saw approximately 35% cell death. Next, we determined the effects of
transiently secreted soluble factors on K562 cells cultured in the upper chamber
of the transwell (TSF), and here we saw protection from cell death at
approximately 10%. We then examined the effects that direct adhesion to HS-5
stroma cells as well as secreted soluble factors on imatinib-induced K562 cell
death (SF+A). Here we observed an even greater protection from cell death at
5%. Lastly, we examined the effects of HS-5-derived stable soluble factors alone
on apoptosis by using HS-5 conditioned media (CM). Here we saw 15% cell
death. Taken together, these data revealed that the co-culture model was not
required for the production of the protective soluble factors produced by HS-5. It
also revealed that HS-5 conditioned media contained stable soluble factors that
provided protection against imatinib-induced cell death. Therefore, to simplify our
bone marrow stroma model, we utilized HS-5-derived conditioned media in our
subsequent experiments.
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Figure 14: Co-culture Bone Marrow Transwell Stromal Model. (A) Co-culture
transwell model system of K562 chronic myeloid leukemia (CML) cultured in: i)
regular media (RM: RPMI + 10% FBS, 1% Penicillin /Streptomycin); ii) the upper
chamber of the transwell system with HS-5-secreting transient soluble factors
(TSF) or with direct adhesion to HS-5 stroma cells (SF+A); iii) .HS-5-derived
conditioned media (CM: RM collected after 3-hour incubation with HS-5 cells).
(B) Annexin V apoptosis assay of conditions described in A.
Characterizing Conditioned Media
Collecting Conditioned Media beyond 3 Hours does not Provide Greater
Protection against Imatinib-Induced Cell Death
To verify whether 3-hour HS-5-derived conditioned media provided the
best protection against imatinib-induced cell death, we generated the conditioned
media as described before, however, instead of only collecting at 3 hours it was
collected at varying time-points: 1, 3, 6 and 24 hours.
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As seen in Figure 15, our data revealed that conditioned media generated
beyond 3 hours did not provide greater protection from death induced by 500 nM
of imatinib.

Figure 15: The Effects of Conditioned Media Collected at Various Times on
Imatinib-Induced Cell Death in K562 CML Cells. HS-5 stromal cells cultured to
75-80% confluency in regular media were incubated for 1, 3, 6, 24 hours in fresh
media. Cell death was measured using the Annexin V apoptosis assay following
treatment with 500 nM of imatinib for 48 hours. Results were analyzed using flow
cytometry.
Conditioned Media Stored for up to One Week Still Provided Protection
against Imatinib-Induced Cell Death
To determine the effects of storage on the protective characteristic of 3
hour-derived conditioned media, we cultured K562 cells in regular media and
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conditioned media that was freshly collected, one day and one week old. Oneday and one-week old conditioned media were stored at -80°C.
After treating K452 cells with 500 nM of imatinib, our results were
analyzed with Annexin V apoptosis assay. Figure 16 reveals that 3-hour-derived
conditioned media that was stored at -80°C for up to one week could still protect
K562 CML cells from death induced by imatinib. This confirmed that HS-5derived soluble factor(s) in the conditioned media is stable and does not have a
short half-life. To ensure consistency and preserve the integrity of our data, we
did not store conditioned media for longer than one week.

Figure 16: The Effects of Storage on 3-Hour-Derived Conditioned Media. To
make the time-dependent conditioned media, HS-5 stromal cells were grown to
75-80% confluency in regular media (RM) for 3 hours. Media was then collected
and used fresh, after one day of storage at -80°C or after one week of storage.
Cell death was measured using the Annexin V apoptosis assay following
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treatment with 500 nM of imatinib for 48 hours. Results were again analyzed
using flow cytometry.
Serum is not Required for Production of the Protective Soluble Factor(s)
Found in HS-5-Derived Conditioned Media
We next wanted to determine if HS-5 human stromal cells require serum
to produce the activate component in conditioned media. To answer this question
we examined whether serum-free conditioned media (SF-CM) can still protect
K562 cells from apoptosis induced by imatinib. HS-5 stromal cells were allowed
to incubate for 3 hours in regular media void of serum. This SF-CM was then
collected and supplemented with 10% FBS then utilized in our experiments. As
before, K562 cells were cultured in regular media (RM), conditioned media (CM)
and SF-CM. Our results were analyzed using the Annexin V apoptosis assay
followed by flow cytometry analysis.
As seen in Figure 17, HS-5 stromal cells were capable of producing their
protective soluble factor(s) in the absence of FBS. Additionally, since media
containing serum is more difficult to fractionate, these data demonstrates that
future studies to identify the protective component of conditioned media using
fractionation can be readily accomplished with this SF-CM.
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Figure 17: The Effects of Serum-Free Conditioned Media on ImatinibInduced K562 Cell Death. To make the time-dependent serum-free (SF)
conditioned media, HS-5 stromal cells were grown to 75-80% confluency in
regular media (RM) for 3 hours. Media was then collected and 10% fetal calf
serum (FBS) was added. SF-CM was used fresh, after one day of storage at 80°C or after one week of storage. Cell death was measured using the Annexin V
apoptosis assay following treatment with 500 nM of imatinib for 48 hours. Results
were again analyzed using FACS.
Conditioned Media does not Convey a Growth Advantage to K562 CML
Cells
Given our previous results which show that conditioned media protects
K562 cells from death induced by imatinib within our bone marrow stromal
model, we decided to investigate whether conditioned is capable of increasing
the rate of K562 cell proliferation and DNA synthesis.
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Using trypan blue exclusion staining method, Figure 18A shows that when
cells were counted over the course of six days, there was no increase in cell
proliferation in K562 cells regardless of culture conditions.
To verify these results, the rate of DNA synthesis, which is indicative of
cell proliferation, was also measured via BrdU incorporation staining and
detection with a FITC-conjugated anti-BrdU antibody. Figure 18B shows that
DNA synthesis is also not increased in conditioned media. Figure 18C is a
representative of three independent BrdU incorporation staining assays.
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Figure 18: The Effects of Conditioned Media on K562 Cell Proliferation and
DNA Synthesis. (A) 50,000 K562 cells were cultured in regular media or
conditioned media and total cell count was determined every 24 hours using
trypan blue exclusion staining. Results and standard deviation represents the
average of 4 independent experiments. (B) The rate of DNA synthesis was
determined by 5-bromo-2-deoxyuridine (BrdU) antibody staining. 2.5 x 105 K562
cells/mL were cultured in regular media or conditioned media for 24 hours then
pulsed with 30 µg/mL of BrdU for 30 minutes. Cells were then fixed with ethanol
and BrdU incorporation was detected using FITC-conjugated anti-BrdU antibody.
Data acquisition and analysis were done using FACS. (C) Representative figure
of BrdU incorporation staining (n=3).
Heat-Inactivated Conditioned Media does not Protect against Imatinib
Mesylate-Induced Cell Death
Cytokines are proteins that initiate cellular communication. To determine if
the HS-5-derived protective soluble factor(s) found in conditioned media is a
cytokine we cultivated K562 CML cells in regular media and heat-inactivated
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conditioned media, treated them with 500 nM imatinib for 48 hours then
performed an Annexin V apoptosis to determine cell death. Results were
analyzed via FACS.
Figure 19 shows that when K562 CML cells were cultured in heatinactivated conditioned media there was no protection from death induced by
imatinib. This demonstrates that the protective soluble factor in HS-5 conditioned
media is a protein.
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Figure 19: Heat-Inactivated Conditioned Media does not Protect K562 Cells
Against Imatinib-Induced Cell Death. K562 cells were cultured for 3 hours in
either regular media or conditioned media that was heat-inactivated at 95°C for
10 minutes. Cells were treated with 500 nM imatinib or 0.1% DMSO for 48 hours.
Cell death was measured using Annexin V apoptosis assay followed by
fluorescence-activated cell sorting analysis.
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HS-5-Derived Conditioned Media Protects K562 and KU812 CML Cell Lines
from Death Induced by Imatinib Mesylate
Results from our co-culture bone marrow stromal model had revealed that
HS-5 conditioned media alone can also protect K562 CML cells from imatinibinduced cell death. We wanted to determine whether the effects we saw was cell
line specific by doing a dose response profile. To address this question, we
performed an imatinib-dose response profile using the CML cell lines, K562 cells
and KU812, which is a pre-basophilic cell line that originated from the peripheral
blood of a CML patient in blast crisis phase. Cells were cultured in regular media
or conditioned and treated with increasing doses of imatinib (0, 125, 250, 500 nM
imatinib) for 48 hours.
The results of the Annexin V apoptosis revealed that exposing either K562
or KU182 cells to conditioned media for 3 hours before drug treatment was
sufficient to inhibit apoptosis induced by imatinib (Figures 20A and B) and
suggested that the protective effects of conditioned media is not cell-line specific.
Additionally, we performed a clonogenic assay, or colony formation assay,
to determine whether conditioned media increased the ability of K562 cells to
divide and form colonies. The clonogenic assay is an in vitro cell survival assay
based on the ability of a single cell to grow into a colony. It is a measure of
cancer cells’ ability to repopulate and form colonies in semisolid media. The
colony is defined to consist of at least 50 cells.
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First, we wanted to determine the optimal K562 cell concentration to use
for the clonogenic assay. To determine this, we performed clonogenic assays
using varying concentrations of K562 cells to obtain a cell-density profile. As
shown in Figure 20C, in the absence of imatinib, conditioned media did not
increase the clonogenic survival of K562 cells across the differing cell
concentrations indicated. Additionally, in the absence of imatinib, the initial cell
concentrations of 2,500 and 5,000 cells provided too few colonies at the end of
10 days to justify the use of these concentrations. Therefore, we utilized the initial
cell concentration of 10,000 cells in our subsequent clonogenic assays to ensure
that there would be enough viable colonies to count, even after high-dose
imatinib treatment.
Figure 20D shows that when K562 cells are treated with varying
concentrations of imatinib, the clonogenic survival of those cells cultured in
conditioned media was increased across all imatinib concentrations when
compared to those control cells cultured in regular media. Taken together, these
data indicate that not only does conditioned media protect from imatinib-induced
apoptosis or cell death but also results in a higher percentage of cells capable of
dividing and repopulating.
Finally, as shown in Figure 20E, removal of K562 cells from conditioned
media into regular media partially reverses resistance to imatinib-induced cell
death. This suggests that imatinib-resistance in CML cells occurs in the presence
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of HS-derived soluble factors and in the absence of the soluble factors CML cells
become re-sensitized to the apoptotic effects of imatinib.
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Figure 20: HS-5-Derived Conditioned Media Protects K562 and KU182 CML
Cells from Death Induced by Imatinib. (A) K562 or (B) KU182 cells were
cultured in either regular media or conditioned media for 3 h and before the
addition of various concentrations of imatinib or 0.1% DMSO for 36 hours. Cell
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death was measured using Annexin V apoptosis assay followed by fluorescenceactivated cell sorting analysis. % Drug-specific apoptosis was calculated by
subtracting the background cell death in control DMSO-treated cells from drug
treated cell death. A, Conditioned media significantly protects K562 cells from
imatinib-mediated cell death (P < 0.05, analysis of covariance). B, Conditioned
media significantly protects KU182 cells from imatinib-mediated cell death (P <
0.05, analysis of covariance). C, Cell-density profile of K562 cells shows similar
clonogenic survival in regular media and conditioned media. K562 cells were
cultured in regular media or conditioned media without imatinib. After 6 hours
incubation at 37°C, 5% CO2, cells were cultured in 0.3% agar made of regular
media or conditioned media and containing their respective imatinib
concentrations. Cells were allowed to incubate at 37°C, 5% CO2 for 10 days. Cell
colonies (>50 cells) were counted. Representative figure in triplicate (n = 3
independent experiments). The starting concentration of 10,000 cells was used in
subsequent clonogenic assays. D, Conditioned media increases the clonogenic
survival of K562 CML cells treated with imatinib. K562 cells were cultured in
regular media or conditioned media and treated with increasing concentrations of
imatinib as depicted. After 6 hours incubation at 37°C, 5% CO2, cells were
cultured in 0.3% agar made of regular media or conditioned media and
containing their respective imatinib concentrations. Cells were allowed to
incubate at 37°C, 5% CO2 for 10 days. Cell colonies (>50 cells) were counted.
Representative figure in triplicate (n = 3 independent experiments). E, Removal
of conditioned media partially reverses resistance to imatinib (P < 0.05, Student ttest). K562 cells were grown in either conditioned media or regular media for 3
hours. Following 3 hours, appropriate samples were removed from conditioned
media and placed in regular media for an additional 3 hours. Cells were treated
with 500 nmol/L imatinib for 36 hours and apoptosis was measured by Annexin V
positivity. Representative figure of experiments done in triplicates.
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Conditioned Media from Non-Stromal Cell Lines do not Protect K562 CML
Cells from Death Induced by Imatinib Mesylate
Some cells are capable of secreting their own soluble factors via an
autocrine loop and condition their own media. We investigated whether the
protection against cell death that we observed using HS-5-derived conditioned
media was specific to this human stromal cell type. To address this, we
generated conditioned media from several other non-stromal cells. K562 CML
cells, U937 lymphoma cells and 8226 myeloma cells were incubated in regular
media for three hours, after which their conditioned media was collected. To
perform the experiment, K562 cells were cultured for three hours in regular
media and the conditioned media of the different cell lines previously described.
The cells were then treated with 500 nM of imatinib for 48 hours. An Annexin V
apoptosis assay was performed followed by flow cytometry analysis.
As you can see in Figure 21, there was no protection from imatinibinduced cell death in K562 cells cultured in its own conditioned media, as well as
in conditioned media from U937 and 8226 cell lines. This suggests that the
secreted, protective soluble factor(s) responsible for conferring the imatinibresistant phenotype are specific to bone marrow stromal cells.
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Figure 21: Conditioned Media from Non-Stroma Cell Lines does not Protect
K562 CML Cells from Death Induced by Imatinib. K562 cells were cultured for
3 hours in either regular media or conditioned media generated from K562, U937
and 8226 cell lines. Cells were treated with 500 nM imatinib or 0.1% DMSO for
48 hours. Cell death was measured using Annexin V apoptosis assay followed by
fluorescence-activated cell sorting analysis.
Conditioned Media Protects K562 CML Cells from Death Induced by 2nd
Generation BCR-ABL Inhibitors, Nilotinib and Dasatinib
One of the shortcomings of imatinib therapy stems from the fact that, over
the course of treatment, many patients develop resistance which results in
relapse and disease progression. Studies have shown that imatinib resistance is
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often caused by point mutations in the BCR-ABL tyrosine kinase domain [113,
161]. This discovery has led to the design and development of more potent,
second generation kinase inhibitors that target imatinib-resistant BCR-ABL
mutants. Dasatinib (Sprycel, BMS-354825, Bristol-Myers Squibb) and nilotinib
(AMN107) represent two potent second-generation BCR-ABL inhibitors, both of
which are more potent than imatinib and show considerable efficacy against most
of the well-characterized BCR-ABL mutants. Both imatinib and nilotinib bind to
the inactive conformation of BCR-ABL, although nilotinib was designed to provide
a better topological fit to the enzyme’s tyrosine kinase domain and binds with
approximately thirty times higher affinity than imatinib. In contrast, dasatinib binds
both the active and inactive conformations of BCR-ABL kinase due to its less
stringent conformational requirements for binding and it is a less selective kinase
inhibitor, targeting SRC kinase family members as well. It is approximately 300
times potent than imatinib against wild-type BCR-ABL expressing cells and,
therefore, inhibits BCR-ABL kinase activity at low-nanomolar concentration
(between 0.75 to 1.0 nM).
As shown in Figures 22A and B, conditioned media protects from both
nilotinib- and dasatinib-induced cell death. These data indicate that the
development of more potent BCR-ABL inhibitors will not circumvent resistance
associated with exposure of CML cells to soluble factors produced by the bone
marrow microenvironment.
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Figure 22: HS-5-Derived Conditioned Media Protects K562 CML Cells from
Death Induced by 2nd Generation BCR-ABL Inhibitors, Nilotinib And
Dasatinib. K562 cells were allowed to incubate for either 48 hours (nilotinib) or
24 hours (dasatinib). Conditioned media significantly protects K562 cells from (A)
nilotinib-mediated cell death (P < 0.05, analysis of covariance) and (B) dasatinibmediated cell death (P < 0.05, analysis of covariance). Representative graph in
triplicates (n = 2 independent experiments)
Conditioned Media Activates STAT3 in K562 and KU812 CML Cell Lines
Signal transducers and activators of transcription (STATs) are members of
a family of transcription factors that were originally characterized as mediators of
cytokine- and growth factor-induced signaling. Many of the growth factors and
cytokines reported to be expressed in the HS-5 cell line are known activators of
STAT3 and STAT5, including granulocyte-macrophage colony-stimulating factor,
G-CSF, interleukin-6, and vascular endothelial growth factor [162-167]. Thus, to
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determine the mechanism(s) of drug resistance observed in conditioned media,
we decided to exam the roles of both STAT3 and STAT5 within our bone marrow
stromal model. We first examined the effects of conditioned media on STAT3
activation. We wanted to determine whether culturing K562 cells in conditioned
media caused an increase in the phosphorylation of STAT3.
To address this question, we performed Western blotting of K562 and
KU812 CML cell lines cultured in regular media or conditioned media across
various time points and used antibodies to probe for pTyr705-STAT3. Total
STAT3 and β-actin serve as loading controls. As shown in Figures 23A and B, a
rapid and sustained increase in pTyr705-STAT3 levels is observed across the
indicated time points in both K562 and KU182 cells cultured in conditioned media
as compared to those cells cultured in regular media. This suggests that our
drug-resistant phenotype may be due to the anti-apoptotic affects of increased
STAT3 activation and also demonstrates that our results were not cell-line
specific.
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Figure 23: STAT3 Phospho-Y705 is Increased in K562 and KU812 CML Cells
Cultured in Conditioned Media. (A) K652 cells were cultured in regular media
or conditioned media for the time points indicated. Cells were collected, lysed,
and analyzed for either pTyr705 or total STAT3 via Western blotting. β-actin was
used as a loading control. (B) KU812 cells were cultured in RM or CM for the
time points indicated. Cells were collected, lysed, and analyzed for either
pTyr705 or total STAT3 via Western blotting. β-actin was used as a loading
control. Representative figure (n = 3 independent experiments).
STAT3 Activation in CML Cells is BCR-ABL-Independent
Previous studies have shown that BCR-ABL activates STAT3 by
phosphorylating Ser727 via the MEK pathway [168]. To determine whether
conditioned media-mediated STAT3 activation in CML cells is BCR-ABL
dependent, we cultured K562 cells in regular media or conditioned media for 3
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hours, then inhibited BCR-ABL signaling by treating cells with varying doses of
imatinib for 48 hours. Cells were subsequently lysed followed by Western blotting
for p-Y705 STAT3 and total STAT3 as a loading control.
We see in Figure 24 that treating K562 cells cultured in conditioned media
with increasing concentrations of imatinib did not reduce STAT activation. In fact,
there is an increase in the basal levels of p-Y705 STAT3 in cells grown in
conditioned media when compared to those cultured in regular media and there
is also sustained STAT3 activation in the presence of imatinib. This data lends
greater support to our previous findings that our drug-resistant phenotype may be
due to the anti-apoptotic affects of increased, aberrant STAT3 activation in CML
cells cultured in conditioned media.

Figure 24: Basal Phospho-Y705 STAT3 is Increased in K562 CML Cells
Cultured in Conditioned Media and is Sustained in the Presence of
Imatinib. K562 cells were cultured in regular media or conditioned media for 3
hours prior to treating cells with varying doses of imatinib for 48 hours and
followed by Western blotting for pSTAT3 and total STAT3.
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STAT5 activation is BCR-ABL-dependent
Previous work done by de Groot revealed that BCR-ABL-mediated STAT5
activation can contribute to K562 leukemic cells’ transformation [169]. To
investigate the potential contribution of STAT5 activation in our drug resistant
phenotype seen in conditioned media, we decided to also examine whether
STAT5 activation in our model is BCR-ABL dependent. As before, we cultured
K562 cells in regular media or conditioned media for 3 hours, inhibited BCR-ABL
signaling with varying doses of imatinib for 48 hours and performed Western
blotting for p-Y694 STAT5, with total STAT5 used as a loading control.
In contrast to our observations with STAT3, culturing K562 cells in
conditioned media did not increase the basal levels of pSTAT5 (Figure 25).
Furthermore, pSTAT5 levels were equally inhibited regardless of the culture
condition. This indicates that STAT5 activation is BCR-ABL-dependent and
eliminates STAT5 as a mediator in the drug-resistant phenotype conveyed by
conditioned media.
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Figure 25: K562 Cells Cultured in Conditioned Media Show Equal Levels of
Phospho-Tyr STAT5 and Equal Inhibition of Phospho-Tyr STAT5 after
Imatinib Treatment. K562 cells were cultured in regular media or conditioned
media for 3 hours; cells were treated with varying doses of imatinib for 48 hours
and probed for pSTAT5 and total STAT5 via Western blotting.
STAT3 Activation is not SRC-Dependent
Previous studies have shown that STAT3 activation can occur via
activation of c-SRC, a member of the proto-oncogenic tyrosine kinases [170]. To
examine whether STAT3 activation within our model is also being mediated by
SRC, we cultured K562 cells in regular media or HS-5-derived conditioned
media, then treated the cells with increasing concentrations of the dual BCRABL/SRC-kinase inhibitor, dasatinib, for 24 hour, followed by Western blotting for
pY705 STAT3 and p-SRC. Total STAT3 and GAPDH were used as loading
controls.
Work done in our lab revealed that while dasatinib inhibited p-SRC
activity, it did not have any inhibit p-Y705 STAT3 activity (Figure 26). This
suggests that STAT3 activation in conditioned media is also independent of SRC
activity.
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Figure 26: Dasatinib Inhibited Phospho-SRC Activity but not Phospho-Y705
STAT3 Activity. Treating K562 CML cells with dasatinib inhibited levels of pSRC family members but did not attenuate the levels of pSTAT3 when K562 cells
were cultured in CM. K562 cells were grown in regular media or conditioned
media, and then treated with increasing doses of the dual BCR-ABL/SRC-kinase
inhibitor, dasatinib, for 24 hours. This was followed by Western blotting for pY705 STAT3 and p-SRC. Total STAT3 and GAPDH were used as loading
controls. Representative figure (n = 3 independent experiments).
Protein Expression Levels of STAT3 Downstream Targets are Increased in
K562 Cells Cultured in Conditioned Media
We next examined whether increased activation of STAT3 corresponded
with an increased expression of its downstream targets, Bcl-xL, Mcl-1 and
survivin.
Previous reports indicated that inhibition of BCR-ABL results in decreased
expression of STAT5-regulated genes including Bcl-xL (24). As shown in Figure
27, while basal levels of Bcl-xL, Mcl-1 and survivin were not increased in K562
cells cultured in conditioned media compared to those cultured in regular media

90

(0 nM imatinib), when those cells were treated with imatinib in the context of
conditioned media these protein expression levels were sustained. Specifically,
we observed that, in the presence of 500 nmol/L imatinib, Bcl-xl, Mcl-1, and
survivin were increased by 4.19 ± 1.82, 3.48 ± 1.84, and 7.0 ± 3.41, respectively
(n = 3 independent experiments) when cells were cultured in conditioned media
compared with cells cultured in regular media. These data suggest that activation
of STAT3 may be responsible for persistent expression of STAT-regulated genes
despite inhibition of STAT5 following imatinib treatment.
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Figure 27: The Effects of Conditioned Media on STAT3 Downstream
Targets, Bcl-Xl, Mcl-1 and Survivin. K562 CML cells were cultured in regular
media or conditioned media for 3 hours then treated with imatinib in a dosedependent manner for 48 hours. Western blot analysis was done with specific
antibodies to Bcl-xl, Mcl-1, and survivin as described in Materials and Methods.
Western blots showing: (A) Bcl-xl; (B), Mcl-1; and (C), survivin. β-actin was used
as a loading control. Representative figure (n = 3 independent experiments).
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Reducing STAT3 Levels with siRNA Increases Sensitivity to Imatinib
Mesylate in Conditioned Media
SiRNA technology was used to determine the causative role for activation
of STAT3 with respect to mediating resistance to imatinib when K562 cells were
cultured in conditioned media. Figure 27A depicts the timeline used in performing
these time-course experiments.
As shown in Figure 28B, STAT3 was reduced at 84 hours and remained
reduced for 120 hours. Based on these time-course experiments, apoptotic
assays were designed as follows: K562 CML cells were transfected with either a
control siRNA or STAT3 siRNA and this process was repeated 36 hours later to
ensure that STAT3 gene expression remained silenced; 84 hours following
imatinib treatment, control siRNA and STAT3 siRNA-transfected cells were
treated with either 250 nmol/L imatinib or vehicle control for 36 hours (120 h after
initial transfection with siRNA) and apoptosis was detected by Annexin V binding.
Because some tumor types require STAT3 for survival, we first analyzed whether
reducing STAT3 levels with siRNA was sufficient to induce apoptosis when cells
were cultured in either regular media or conditioned media. As shown in Figure
28C, reducing STAT3 levels (120 hours time point) with siRNA did not cause
apoptosis in either growth condition. However, reducing STAT3 levels sensitized
K562 to imatinib-induced cell death when K562 cells were grown in conditioned
media but not in regular media (see Figure 28D for a representative figure).
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In Figure 28E we graphed the geometric mean of the ratios of each group
depicted, showing the 95% confidence intervals and the P-values. We used the
geometric mean instead of the arithmetic mean because with the arithmetic
mean values below 1 are limited to numbers between 1 and 0. But values above
1 are limited to 1 and infinity. Therefore, using the geometric mean enabled us to
address this asymmetry. The first group we analyzed was those cells transfected
with the control siRNA and treated with imatinib regardless of culture conditions.
Our results in Figure 28E show that in the control siRNA-transfected cells,
there was a significant difference in imatinib-specific cell death seen in K562 cells
cultured in regular when compared to those cultured in conditioned media. We
next analyzed the STAT3 siRNA-transfected cells that were treated with imatinib
in either regular media or conditioned media. Our results show that when STAT3
is knocked-down using siRNA there was no significant difference in imatinibinduced apoptosis in cells cultured in regular media compared to those cultured
in conditioned media. In essence, we were able to reverse the drug-resistant
phenotype seen in conditioned media by knocking-down STAT3. We then
analyzed those cells cultured in regular media, regardless of their transfection
state. As seen in Figure 28E, our results show that when cultured in regular
media, whether or not STAT3 is knocked-down, there was no significant
difference in apoptosis induced by imatinib. Lastly, we analyzed those cells
cultured in conditioned media, regardless of their transfection state. Our results
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show that when cultured in conditioned media and STAT3 is knocked-down,
there was a significant difference in apoptosis induced by imatinib.
Taken together, these data indicate that STAT3 contributes to imatinib
resistance only when cells are cultured within the context of bone marrow
stroma-derived conditioned media. Furthermore, these data suggest that STAT3
can compensate for BCR-ABL survival signals and thus represents a potential
BCR-ABL-independent mechanism of drug resistance.
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Figure 28: Reducing STAT3 Levels with siRNA Reverses Imatinib
Resistance in K562 Cells Cultured in Conditioned Media. K562 cells were
cultured in either regular media or conditioned media and treated with either
siRNA to STAT3 or control siRNA. (A), Time line for conducting siRNA
experiments. (B), STAT3 knockdown was confirmed using Western blotting and
STAT3 was noted to be maximally decreased at 84 hours and remained reduced
for at least 120 hours (n = 5 independent experiments). (C), reducing STAT3
levels was not sufficient to cause cell death in cells cultured in regular media or
conditioned media. Mean ± SD of 5 independent experiments. (D, reducing
STAT3 levels enhances sensitivity to imatinib when K562 cells are cultured in
conditioned media. Apoptosis of K562 cells cultured in regular media or
conditioned media, treated with either STAT3 siRNA or control siRNA, in the
presence or absence of 250 nmol/L imatinib was done using the Annexin V
detection of apoptotic cells and fluorescence-activated cell sorting analysis. %
Specific apoptosis was calculated by subtracting background cell death from
imatinib-mediated cell death. (E), Geometric mean of the 5 combined
independent experiments showing the 95% confidence intervals and the
corresponding P-values. The geometric mean was calculated as the 5th root of
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the product of all the members of the data set in all 5 experiments. The formula is
, where ‘a’ represents the data of

depicted as follows:

each experiments (1-5). We decided a priori that a p-value <0.05 is statistically
significant. Representative figure in triplicates (n = 5 independent experiments).
Addition of GM-CSF, IL-6 and VEGF to Regular Media Induces the ImatinibResistant Phenotype Associated with Conditioned Media
Previous studies highlighted the involvement of multiple cytokines in
mediating drug-resistance in CML cells and demonstrate the involvement of more
than one cytokine in stroma-mediated protection of leukemic cells [171].
Therefore, we decided to investigate the role of key cytokines, GM-CSF, IL-6 and
VEGF, on our conditioned media-induced imatinib-resistant phenotype within our
model system. We wanted to determine whether the addition of these STAT3activating cytokines to regular media induce imatinib-resistance in K562 CML
cells. To answer this question we cultured K562 cells for 3 hours in regular media
containing varying concentrations of GM-CSF (0.125 - 2.0 ng/mL), IL-6 (0.25 –
4.0 ng/mL) or VEGF (3.0 – 48.0 ng/mL), treated the cells with vehicle control or
500 nmol/L imatinib for 48 hours and analyzed our results via Annexin V
apoptosis assay followed by FACS analysis.
Our preliminary results indicate that the addition of these cytokines to
regular media induced the imatinib-resistant phenotype that has been observed
in K562 CML cells cultured in conditioned media. Figures 29A and B show that
2.0 ng/mL GM-CSF and 4.0 ng/mL IL-6, respectively, induced the conditioned
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media- associated imatinib-resistant phenotype to K562 cells cultured in regular
media. At 48.0 ng/mL VEGF partially restores this phenotype to K562 cells
cultured in regular media (Figure 28C). Together, these results suggest that
multiple cytokines, including GM-CSF, IL-6 and VEGF, may be involved in
mediating imatinib resistance to CML cells within the context of the bone marrow
stroma.
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Figure 29: The Effects of GM-CSF-, IL-6-, or VEGF-Supplemented Regular
Media on Imatinib-Sensitivity in K562 CML Cells. K562 CML cells were
cultured for 3 hours in regular media supplemented with varying concentrations
of GM-CSF, IL-6 and VEGF as indicated added. After treatment with DMSO
vehicle control or 500 nmol/L imatinib, cells were allowed to incubate 48 hours at
37°C, 5% CO2. Cell death was measure using AnnexinV apoptosis assay and
data was analyzed using FACS. Representative figure (n = 2 independent
experiments).
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CHAPTER X
DISCUSSION AND FUTURE DIRECTION

Over 40 years ago ground-breaking research led to the identification of the
BCR-ABL chimeric oncoprotein as the initial transforming event in chronic
myeloid leukemia (CML). This discovery revolutionized the treatment of CML and
made BCR-ABL an ideal target for drug development. This gave rise to rationally
designed, small molecule signal transduction inhibitors (STI) specific for the
tyrosine kinase domain of BCR-ABL, whose constitutive activation is the hallmark
of BCR-ABL-mediated cell transformation.
The novel BCR-ABL tyrosine kinase (TK) inhibitor, imatinib mesylate
(imatinib; IM), represents the first molecularly targeted therapy in patient care
and has become the gold standard in the treatment for CML patients. By working
as an ATP-mimic that selectively competes for and binds to the TK domain of
BCR-ABL, imatinib essentially stabilizes the oncoprotein in an inactive
conformation that inhibits its enzymatic and transforming activities. The
remarkable efficacy of this targeted-therapy approach to CML treatment is
evidenced by the fact that imatinib produces a complete hematological response
rate, which described the amount of normal leukocyte count in the peripheral
blood, of 95% in newly diagnosed patients. Furthermore, it produces complete
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cytogenetic response, which is the absence of detectable Ph-positive cells from
more than 20 bone marrow cells in metaphase, in 90% of patients with minimal
toxicity.
However, despite imatinib’s efficacy and the efficacy of more potent BCRABL inhibitors such as nilotinib and dasatinib, the emergence drug-resistant CML
challenges us to re-visit our understanding of the mechanisms involved in CML
disease occurrence, progression and drug-resistance. Clinical data arising from
studies targeting BCR-ABL inhibitors indicate that although BCR-ABL inhibitors
are very effective, targeted therapy using a single agent does not eliminate
minimal residual disease (MRD). This is due to the observation that BCR-ABLpositive clones are still detectable by quantitative real time-PCR in patients
undergoing treatment with these inhibitors. Furthermore, these findings are
consistent with clinical data indicating that patients that discontinue imatinib
therapy rapidly relapse to a tumor burden which is as great or greater then before
treatment, suggesting that imatinib does not induce cell death in the stem cell
population or the population capable of self-renewal [172, 173].
Imatinib was specifically designed to bind to and block the ATP-binding
pocket of the BCR-ABL kinase domain while in an inactive conformation.
Mutations within the kinase domain disrupt that conformation and thwart the
ability of imatinib to bind. Therefore, the predominant and most characterized
mechanism of imatinib-resistance is the emergence of clones possessing point
mutations within the kinase domain of BCR-ABL. These observations led to the

104

development of second generation BCR-ABL inhibitors, nilotinib and dasatinib,
which are 30 and 300 times more potent than imatinib, respectively. However,
despite the efficacy of these inhibitors, their use has not remedied the problem of
all chemo-resistant CML associated with kinase mutations. Some patients
present with indomitable pre-existing mutations, such as T315I, which these
inhibitors cannot eradicate, while other patients acquire this mutation and the
resistant phenotype during the course of treatment with these inhibitors.
Furthermore, recent evidence reveals that mutations of the BCR-ABL kinase
domain occur in approximately 40% to 60% of imatinib-resistant patients [174].
Therefore, approximately 50% of these imatinib-resistant CML patients do not
have kinase domain mutations but are resistant to imatinib by alternative means.
This suggests that BCR-ABL-independent mechanisms could contribute to
imatinib-resistance and underscore the need to identify and target BCR-ABLindependent pathways.
Models used to investigate the mechanisms of drug resistance seen in
CML often highlight the cell-autonomous modes of resistance: mutations within
the tyrosine kinase domain of BCR-ABL itself that either block imatinib binding or
impair the ability of the kinase to assume the correct conformation required for
imatinib to bind. But these models often fail to consider the role of the
surrounding cells and tissues, the “microenvironment”, on the cancer itself and
the role of this microenvironment on the emergence of the tumor drug-resistance
phenotype. However, recent studies have draw attention to the involvement of
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the tumor microenvironment in providing cancer cells an escape from
chemotherapy-induced cell death. While studying drug resistance in Ph-positive
acute lymphoblastic leukemia (ALL), William et al. reported on a nonautonomous mechanism of drug resistance involving cytokine signaling within the
hematopoietic microenvironment [139]. This study revealed that the contribution
of BCR-ABL-independent mechanisms was capable of protecting CML cells from
imatinib-induced cell death. Therefore, the use of an in vitro non-autonomous
model of drug resistance may provide further insights into the role of host-derived
stimuli on CML cells in conferring resistance to BCR-ABL inhibitors and may
provide a greater comprehension of how to combat this mechanism of
resistance.
To investigate the role of the bone marrow microenvironment on
resistance to BCR-ABL inhibitors, we utilized an in vitro bone marrow stromal
model that exposes CML cells to multiple soluble factors produced by bone
marrow stroma cells. The human bone marrow stromal cell line, HS-5, served as
the model of the bone marrow microenvironment as it closely approximates the
bone marrow-associated cytoprotection observed in drug-treated leukemia
patients. HS-5 is fibroblastic and has been shown to secrete numerous cytokines
that are capable of supporting the ex vivo expansion of mature and immature
hematopoietic cells and their progenitors ([175]. Two hematopoietic CML cell
lines were used to model the disease: K562 cells originated in the bone marrow,
are highly undifferentiated and were derived from the pleural effusion of a CML
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patient in blast crisis phase; KU812 cells are pre-basophilic and originated from
the peripheral blood of a blast-crisis-phase CML patient.
Previous work done in our laboratory revealed that adhesion of K562 CML
cells to fibronectin could provide cell adhesion mediated-drug resistance (CAMDR) against imatinib-induced cell death through anti-apoptotic integrin-mediated
signaling [135]. Similarly, our initial set of experiments using a co-culture
transwell model system revealed that direct adhesion of K562 cells to HS-5
stoma cells conferred protection against cell death induced by imatinib, possibly
through a similar mechanism. Interestingly, however, was the observation that
HS-5-derived soluble factors were also capable of modulating imatinib response
in CML cells and confer resistance. This data indicates that both direct contact
with the bone marrow stroma and soluble factors produced by supporting stroma
cells play a role in the emergence of the CML drug-resistant phenotype. This
data also lends support to previous observations that, in addition to targeted
therapy against BCR-ABL, the tumor-microenvironmental interactions may play a
crucial role in protecting CML cells from the anti-apoptotic and anti-proliferative
effects of imatinib. To delineate the contributions of bone marrow stroma-derived
soluble factors on resistance to BCR-ABL inhibitors and to simplify our model the
data presented in this dissertation were obtained from the use of HS-5-derived
conditioned media.
It has been demonstrated here that imatinib induces a high rate of cell
death in CML cells cultured in regular media (RM: RPMI + 10% fetal bovine
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serum). However, using the same media conditioned for three hours by the HS-5
human stroma cells (CM) is sufficient to cause resistance to imatinib-induced cell
death in K562 and KU182 CML cells. Since HS-5 stromal cells produce cytokines
that support the growth and differentiation of HSCs, this data suggests that HS-5derived soluble factor(s) may be involved in mediating this imatinib-resistant
phenotype in CML cells. Furthermore, HS-5 conditioned media could be stored at
-80°C and retain its ability to produce imatinib resistance in these CMLS cells,
while heat-inactivated conditioned media lost this ability. These data indicate that
the soluble factor(s) conferring resistance to imatinib is quite stable and capable
of preserving its function during the freezing and thawing process. Additionally,
heat-inactivation of conditioned media would destroy its protein components,
which includes growth factors and cytokines. The observation that heatinactivated conditioned media restores imatinib-sensitivity to CML cells
demonstrates that the protective component in conditioned media is a protein.
Based on findings of similar studies, the hematopoietic cytokine granulocyte
macrophage-colony stimulating factor (GM-CSF) and interleukin 6 (IL-6) are two
potential cytokines that may be involved in mediating the BCR-ABL-independent
imatinib-resistant phenotype seen in our model.
While HS-5-derived conditioned media increased the clonogenic survival
of K562 cells, exposure of CML cells to the soluble factors in conditioned media
did not lead to an increase in cell proliferation. This indicates that the soluble
factor(s) mediate imatinib-resistance through cell survival pathways. There are
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several well-characterized cytokine-receptor-activated cell survival pathways that
may be involved in promoting clonogenic survival of these cells. The Janus
activated kinase (JAK)/STAT signal transduction pathway is important in
converting cytokine-receptor signals into downstream survival signals and is
often constitutively activated in hematopoietic malignancies. Studies show that in
BCR-ABL-expressing cells, constitutive activation of JAKs is associated with
constitutive STAT3 Try-705 phosphorylation. Studies show that STAT5 is also
constitutively activated in CML cells. Other survival pathways that may enhance
the clonogenic survival of CML cells are the anti-apoptotic phosphatidylinositol 3kinase (PI3K)/AKT signaling pathway, whose activation has been shown to not
only be involved in BCR-ABL-mediated cell transformation but also resistance to
BCR-ABL inhibitors. Additionally, BCR-ABL also signals through the extracellular
signal regulated kinase 1/2 (ERK-1/2) pathway and has been implicated in the
anti-apoptotic activities of BCR-ABL.
Data presented here revealed that when CML cells were no longer
exposed to the protective soluble factor(s) associated with HS-5 conditioned
media and were re-cultured in regular media, the imatinib-resistant phenotype
diminished. This demonstrates that withdrawal of CML cells from bone marrow
stroma-secreted soluble factor(s) was sufficient to re-sensitize these cells to the
apoptotic effects of imatinib. It is possible that this observation is attributable to
the termination of cytokine-receptor-mediated signaling. Furthermore, this data
reveals a direct correlation between the presence of HS-5-derived soluble factors
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and the emergence of imatinib resistance, an observation that has also been
highlighted in other studies.
The hypothesis within this dissertation is based on the importance of
soluble factors specific to the bone marrow microenvironment in promoting
chemoresistance in CML cells. To accurately test this hypothesis it was important
to investigate whether K562 CML cells could condition its own media via
autocrine secretion of its own soluble factors and induce chemoresistance.
Additionally, we investigated whether other non-stromal cell lines were capable of
conveying protection against cell death induced by imatinib. In either case, if
there is protection against cell death induced by BCR-ABL inhibitors then this
would demonstrate that the bone marrow microenvironment may not be
responsible for providing chemo-resistance to CML cells and would discredit its
role in modulating drug response within our model. Conditioned media from K562
CML cells and two hematopoietic cell lines, U937 and 8226, were generated in
the same manner as HS-5-derived conditioned media: these cells were cultured
in regular media for 3 hours, enabling the media to become conditioned by the
different cell lines; the conditioned media was then collected by centrifugation to
remove debris and utilized in subsequent experiments. K562 CML cells were
cultured in regular media and several types of conditioned media, as previously
described. The cells were treated with imatinib for 48 hours to induce cell death,
which was measured using the Annexin V apoptosis assay. Our data revealed
that of the different conditioned media generated, only HS-5-derived conditioned
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media was capable of conveying imatinib-resistance in K562 CML cells. This
data validated the unique role and importance of soluble factors specific to the
bone marrow stroma in protecting CML cells from death induced by imatinib.
There are numerous bone marrow stroma-derived soluble factors and
cytokines involved in the growth and differentiation hematopoietic cells that may
also be crucial in conferring resistance to BCR-ABL inhibitors. According to
Torok-Storb (1999), the human HS-5 stroma cell produces a cocktail of cytokines
that include IL-6, GM-CSF, G-CSF and VEGF. It is conceivable that these
cytokines could confer protection against imatinib-induced cell death to varying
degrees either individually on in combination with each other. In fact, while
studies by Wang et al. focused on the role of the autocrine secretion of GM-CSF
in mediating resistance to BCR-ABL inhibitors in CML cells [140], Weisberg et al.
emphasized the involvement of the bone marrow stroma as a whole in mediating
protection against CML cell death by using a cocktail of stroma-derived cytokines
[171].
Our data from the bone marrow stromal model lends credence to the
involvement of survival signaling mediated by stroma-derived soluble factors in
the emergence of chemo-resistant CML. This is also evidenced by our
observations that neither nilotinib nor dasatinib are capable of overriding the
protective effects of HS-5-secreted soluble factors on K562 CML cells. This
demonstrates that even though one inhibitor was designed to bind more
stringently to the tyrosine kinase domain of BCR-ABL and the other was
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designed to recognize and bind to both its active and inactive conformations, the
development and use of these more potent, rationally-designed inhibitors was not
sufficient to address this mechanism of resistance involving the bone marrow
microenvironment. There is growing interest in research to target components of
the hematopoietic tumor microenvironment as a way to enhance the efficacy of
targeted therapy against CML. While research that addresses BCR-ABLindependent mechanisms of imatinib resistance have gained momentum, there
are also concerns about the effects that targeting the bone marrow
microenvironment may have on normal hematopoiesis and surrounding cells.
Studies suggest that the best initial approach is to target individual signal
transduction pathways that are constitutively activated in malignant
hematopoietic cells.
BCR-ABL’s modular domains make it capable of activating several signal
transduction pathways that can contribute to enhanced CML cell survival,
including Ras/ERK, PI3K/AKT, and STAT5 signal transduction pathways. These
pathways can also be activated by external signals including growth factors,
cytokines, and interactions with extracellular matrices. Furthermore, studies
suggest that these pathways can be reconstituted in a BCR-ABL-independent
manner by these external signals. Our data supports this observation and reveals
that HS-5-derived soluble factors are capable of BCR-ABL-independent
constitutive STAT3 activation via Tyr-705 phosphorylation. Studies show that
constitutive STAT3 Tyr-705 phosphorylation and activation is mediated by
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activated JAKs. Activated STAT3 homo- or heterodimerizes and translocates to
the nucleus where it leads to the transcriptional activation of STAT3 target antiapoptotic genes.
Studies show that cytokines that are capable of STAT3 activation include
IL-6, vascular endothelial growth factor (VEGF), and GM-CSF. Here we
demonstrate that not only does the exposure of either K562 or KU812 CML cells
to conditioned media derived from HS-5 cells resulted in the rapid and sustained
increase in phospho-Y705 STAT3 levels, but we also show that this exposure to
HS-5-derived soluble factors also led to an increase in the protein expression
levels of STAT3 downstream targets, Bcl-xL, Mcl-1 and survivin. This suggests
that HS-5-derived soluble factors may be involved in the activation of STAT3,
which in turn resulted in STAT3-mediated expression of these anti-apoptotic
proteins. Furthermore, the addition of imatinib does not reduce phospho-Y705
STAT3 levels or the levels of its downstream targets. This demonstrates that
activation of STAT3 is indeed independent of BCR-ABL activity and highlights the
importance of BCR-ABL-independent mechanisms in facilitating the imatinibresistant phenotype. This data also contradicts an earlier observation made by
Coppo et. al. which showed that the constitutive phosphorylation of STAT3 on
Tyr-705 was dependent on BCR–ABL [168]. This difference may be attributable
to the fact that they utilized a hematopoietic cell line that was retrovirally
transduced with a p210-BCR-ABL expressing vector as oppose to utilizing a cell
line obtained from CML patients.
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Since studies show that STAT3 activation can also be accomplished
through the activities of SRC family kinases (SFKs), it was important to
determine whether the increase in BCR-ABL-independent STAT3 activity was
attributable to SFKs. Our data showed that when K562 CML cells were treated
with the dual BCR-ABL/SFK inhibitor, dasatinib, sustained phosphorylation of
STAT3 was still observed in those cells cultured in HS-5-derived conditioned
media, while phospho-SRC levels were attenuated. This observation eliminates
the involvement of SFKs in the increased activation of STAT3 that we observed
in our model and lends greater support to the involvement of HS-5 derived
soluble factors in mediating STAT3 activation, possible through cytokine
receptor-engagement and JAKs activation. While investigating the role of STAT3
activation in K562 CML cells exposed to HS-5 soluble factors and assessing the
mechanism(s) involved in its activation, one interesting and consistent
observation was that the use of increasing concentrations of imatinib resulted in
increased STAT3 activation. In examining this further, other studies have
reported that BCR-ABL can activate STAT5 and STAT1 independently of the
activation of JAKs [154]. Furthermore, a dominant-negative STAT5 was shown to
inhibit colony formation of K562 cells and blocking BCR-ABL was shown to inhibit
STAT5-dependent DNA binding as well as STAT5 target genes, Bcl-xL and Mcl-1
[169, 176-180]. Bcl-xl, Mcl-1, and cyclin D1 represent genes that can be
regulated by either STAT5 or STAT3 activation. Therefore, based on these
observations, we propose that within the bone marrow microenvironment STAT3
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can compensate for BCR-ABL-dependent activation of STAT5-dependent genes,
which are critical for CML cell survival, when STAT5 activity is blocked by BCRABL inhibitors. In support of this hypothesis, our data also indicate that when
K562 cells were treated with imatinib, the levels of Bcl-xL, survivin, and Mcl-1
were increased when cells were cultured in conditioned media compared with
cells cultured in regular media. Together, these data suggest that, depending on
culture conditions, K562 CML cells may have plasticity with respect to STATdependency.
To determine the causal role of STAT3 activation in our drug-resistant
phenotype associated with conditioned media, we reduced STAT3 levels using
siRNA technology. Here we show that this reduction in STAT3 levels led to the
enhanced sensitivity of K562 CML cells to imatinib-induced cell death.
Importantly, this increased imatinib-sensitivity in CML cells was observed only
within the context of the bone marrow stroma model, as reducing STAT3 levels in
regular media did not result in increased cell death. These data highlight the
contribution and significance of BCR-ABL-independent STAT3 activation in
reconstituting BCR-ABL-mediated survival signaling events that promote CML
progression. Furthermore, our data indicate that while the initial BCR-ABL insult
that initiated the disease within the primitive hematopoietic stem cell population is
crucial to CML pathogenesis, clearly soluble factors unique to the hematopoietic
microenvironment are capable of protecting CML cells from the apoptotic effects
of BCR-ABL inhibitors. To address the question recently posed by Charles
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Sawyers in his news brief entitled ‘Where lies the blame for resistance - tumor or
host?’ [181], the synthesis of data presented here, along with data presented in
previous studies, suggest that both the tumor and the host are responsible.
Consequently, the use of BCR-ABL inhibitors alone is not sufficient to address
this type of resistance, which is associated with BCR-ABL-independent STAT3
activation. While BCR-ABL inhibitors target the fusion oncoprotein, it does not
target STAT3. Therefore, these data also provide pre-clinical rationale for
targeting STAT3 in order to increase the efficacy of BCR-ABL inhibitors in
treating drug-resistant CML cells. To that end, a multi-targeted approach to CML
patient care that involves the combined use of BCR-ABL inhibitors and STAT3
inhibitors may prove more effective in addressing this type of drug-resistant CML.
In vitro studies to identify compounds that are highly selective for STAT3 have
highlighted the effectiveness of cisplatin/IS3 295 [182] as well as cucurbitacin Q
[183] in inhibiting STAT3 activation.
Bone marrow stroma-derived conditioned media consists of a complex
mixture of cytokines and other soluble factors that can be source of survival
signals affecting cell differentiation, expansion and survival. The functional
redundancy of many of these soluble factors and their signaling receptors may
converge to activate STAT3 and circumvent cell death induced by BCR-ABL
inhibitors. Since several studies have highlighted the involvement of GM-CSF, IL6 and VEGF in the emergence and progression of hematological malignancies,
we examined the contribution of these cytokines in our drug-resistant phenotype.
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We wanted to determine whether exposure of CML cells to these cytokines can
modulate their response BCR-ABL inhibitors. Here, our data revealed that when
these cytokines were added to regular media in varying concentrations a dosedependent imatinib resistant phenotype emerged. This is evidenced by the
steady reduction in imatinib-induced CML cell deaths, which correlated with
increased cytokine concentrations. The addition of 2.0 ng/mL of GM-CSF, 4.0
ng/mL of IL-6 or 48.0 ng/mL of VEGF to regular media initiated the return of the
imatinib-resistant phenotype associated with HS-5 conditioned media. These
results, which are consistent with observations made in similar studies, indicate
that these cytokines may be working individually or cooperatively to protect CML
cells from death induced by BCR-ABL inhibitors.
Furthermore, data from other studies revealed that conditioned media
from malignant cell lines expressing high levels of phospho-STAT3 also
contained cytokines that are capable of stimulating STAT3 activation, such as IL6. To determine the involvement of cytokines such as IL-6, GM-CSF and VEGF
within our model, their activity in conditioned media could also be impeded using
blocking antibodies. For example, IL-6 signal transduction, which activates
STAT3 through the glycoprotein (gp) 130/JAK pathway and is notable for its
pleiotropic tumor-promoting activities, could be blocked using a gp130-blocking
antibody or an IL-6-blocking antibody (such as BR-3 and 522, respectively;
provided by Cell Sciences, Inc.). Alternatively, to validate the results obtained
from the use of cytokine-blocking antibodies, the gene expression of these
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cytokines in HS-5 cells could also be sequentially silenced using siRNA
technology.
To identify the specific soluble factor(s) causative for imatinib resistance
and STAT3 activation within our model, one global approach is to utilize
multiplexed bead-based assays that efficiently detect and quantify several
cytokines simultaneously (Invitrogen). These assays consist of captureantibodies conjugated to biologically inert beads and are designed to identify
various soluble factors, including cytokines, with enhanced speed and accuracy.
Furthermore, since our data revealed that HS-5 cells do not require serum to
produce the protective soluble factors, we could identify the active soluble
factor(s) in HS-5 conditioned media that confers imatinib resistance by
fractionating the SF-CM into its protein components and performing the Annexin
V apoptosis assay on each fraction. Fractionation could be accomplished in
several ways. Centricon spin columns (Miliipore) can separate the components of
conditioned media by molecular weight. Additionally, fractionation can also be
accomplished using liquid chromatography or mass spectrometry.
Constitutive STAT3 activation is associated with several human
malignancies, including solid tumors and hematological diseases. Interestingly,
we observed that reducing STAT3 levels sensitized imatinib-resistant CML cells
to its apoptotic effects. It is possible that while BCR-ABL-mediated oncogenic
signaling events are being impeded by imatinib, the non-autonomous activation
of STAT3 by soluble factors within the bone marrow microenvironment facilitates
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these signal transduction events (see Figure 30 for proposed model).
Additionally, our data provides preclinical rationale to support the use of STAT3
inhibitors as BCR-ABL-inhibitor sensitizers and for conduction validating our
observations in studies using primary patient specimens. One set of experiments
would be to confirm data presented in other studies that show increased STAT3
activation in primary CML patient samples when compared to healthy bone
marrow donors. Furthermore, cells from CML patient can be used to delineate
whether small molecule inhibitors targeting STAT3, such as phosphotyrosyl
peptides [184], are capable of enhancing the efficacy of BCR-ABL inhibitors
using in vivo models.
Furthermore, patient’s samples could be used to examine whether STAT3
activation enables CML cells to escape complement-dependent cytotoxicity via
CD46 expression. It has been reported that STAT3 activation is capable of
inducing the expression of CD46, one of the complement-regulatory proteins
(CRPs) expressed on the surface of normal and transformed cells. While
complement proteins target bacteria and cancerous cells for lysis [185], cancer
cells often escape elimination by complement proteins. This escape mechanism
is due in part to the expression of this membrane-bound CRP, which inactivates
complement components. It would be of interest to e whether increased STAT3
activation in patient samples also resulted in this escape mechanism.
Studies show that BCR-ABL-positive MRD in some imatinib-resistant CML
cells are characterized by increased activation of the PI3K/AKT and Ras/MEK

119

signal transduction pathways. These pathways are capable of mediating cell
survival by transmitting signals from multiple cell surface receptors to
transcription factors within the nucleus. However, the mechanisms responsible
for the enhanced activation of these survival pathways remain poorly understood.
Future studies may include investigating whether the PI3K/AKT and Ras/MEK
signal transduction remains activated in imatinib-treated CML cells cultured in
conditioned media. Furthermore, a SCID-hu in vivo model could be implemented
to validate the involvement of these pathways in modulating imatinib response in
CML cells.
In conclusion, while imatinib and other BCR-ABL inhibitors are highly
effective in treating CML patients and addressing mechanisms of acquired
resistance, the high rates of patient relapse and the persistence of MRD CML
challenges us to continuously expand our understanding of CML pathogenesis
and seek innovative solutions to combat this disease. Data presented here
demonstrate that targeted therapy using a single agent does not eradicate drug
resistance associated with the bone marrow microenvironment. However, the
use of combinational therapy that targets BCR-ABL as well as stroma-derived
soluble factors promises to increase the efficacy of BCR-ABL inhibitors by
sensitizing cells to their apoptotic effects. This accomplishment would translate
into increased remission rates among CML patients and further revolutionize
oncology therapeutics. Additionally, these data demonstrate the importance of
bone marrow stroma models that consider the tumor microenvironment in
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identifying novel targets that enhance the efficiency of existing targeted drug
therapies.

Figure 30: Proposed Mechanisms of Resistance to BCR-ABL Inhibitors in
Chronic Myeloid Leukemia Cells. Data from our bone marrow stroma model
show increased and sustained STAT3 activation in CML cells. Bone marrow
stroma cells secrete numerous soluble factors that are capable of STAT3
activation. Additionally, soluble factors within the bone marrow microenvironment
may be capable of reconstituting BCR-ABL downstream signaling events, such
as the Ras/MEK and PI3K/AKT cell survival signal transduction pathways.
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